AU2003290032B2 - Trimeric macrocyclically substituted benzene derivatives - Google Patents

Trimeric macrocyclically substituted benzene derivatives Download PDF

Info

Publication number
AU2003290032B2
AU2003290032B2 AU2003290032A AU2003290032A AU2003290032B2 AU 2003290032 B2 AU2003290032 B2 AU 2003290032B2 AU 2003290032 A AU2003290032 A AU 2003290032A AU 2003290032 A AU2003290032 A AU 2003290032A AU 2003290032 B2 AU2003290032 B2 AU 2003290032B2
Authority
AU
Australia
Prior art keywords
nhcoch
tris
mmol
stands
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2003290032A
Other versions
AU2003290032A1 (en
Inventor
Juan R. Harto
Jose Luis Martin
Johannes Platzek
Bjorn Riefke
Heiko Schirmer
Hanns-Joachim Weinmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2003290032A1 publication Critical patent/AU2003290032A1/en
Application granted granted Critical
Publication of AU2003290032B2 publication Critical patent/AU2003290032B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

Trimeric Macrocyclic Substituted Benzene Derivatives This application claims the benefit of the filing date of U.S. Provisional Application Serial No. 60/452,053 filed Mar. 6, 2003. The invention relates to the subjects that are characterized in the claims: new trimeric macrocyclic substituted triiodine and tribromobenzene derivatives, their production and use as contrast media in x-ray diagnosis and MRT diagnosis. During the last decade, impressive advances were achieved in imaging diagnosis. The imaging techniques, such as DAS, CT and MRT, have developed into standard and indispensable tools in diagnosis and interventional radiology and now offer a spatial resolution of less than 1 mm. In addition, the possible applications of these techniques are increased decisively by the use of contrast media. This now wide distribution and acceptance of the contrast media in x-ray diagnosis can be attributed to the introduction of non-ionic monomeric triiodoaromatic compounds in the 1980's, as well as the isoosmolar dimeric iodoaromatic compounds that were introduced in-the 1990's. By these two compound classes, the frequency of contrast medium-induced side effects was reduced to 2-4% (Bush, W. H., Swanson, D. P.: Acute Reactions to Intravascular Contrast Media: Types, Risk Factors, Recognition and Specific Treatment. AJR 157, 1153-1161, 1991. Rydberg, J., Charles, J., Aspelin, P.: Frequency of Late Allergy-Like Adverse Reactions Following Injection of Intravascular Non-ionic Contrast Media. Acta Radiol6gica 39, 219-222, 1998). The use of contrast media in connection with modem imaging techniques now extends from the detection of tumors, for high-resolution vascular visualization, to the quantitative determination of physiological factors such as permeability or perfusion of organs. The concentration of the x-ray contrast medium 2 (here the iodine atom) is decisive for the contrast and the detection sensitivity. Despite further development of the technology, it was not possible to reduce the concentration or the dose to be administered that is necessary for a medical diagnosis. Thus, in a standard CT study, 100 g of substance or more is injected per patient. Although the compatibility of the x-ray contrast media has been improved by the introduction of non-ionic triiodobenzenes, the number of side effects is still always high. Because of very high study numbers of several million per year in x-ray diagnosis, ten thousand patients are 'thus affected. These contrast medium-induced side effects extend from slight reactions such as nausea, dizziness, vomiting, and hives up to severe reactions such as bronchiospasms, or renal failure up to reactions such as shock or even death. Fortunately, these severe cases are very rare and are observed at a frequency of only 1/200,000 (Morcos, S. K., Thomsen, H. S.: Adverse Reactions to Iodinated Contrast Media. Eur Radiol 11, 1267-1275, 2001). The frequency of these side effects, which are also observed as pseudoallergic contrast medium-induced side effects, is, however, increased by about a factor of 3 in atopic patients and by a factor of 5 in patients with a previous history of contrast medium-induced side effects. Asthma increases the risk of severe contrast medium induced side effects by a factor of 6 in non-ionic contrast media (Thomsen, H. S., Morcos, S. K.: Radiographic Contrast Media. BJU 86 (Suppll), 1-10, 2000. Thomsen, H. S., Dorph, S.: High-Osmolar and Low-Osmolar Contrast Media. An Update on Frequency of Adverse Drug Reactions. Acta Radiol 34, 205-209, 1993. Katayama, H., Yamaguchi, K., Kozuka, T., Takashima, T., Seez, P., Matsuura, K.: Adverse Reactions to Ionic and Non-ionic Contrast Media. Radiology 175, 621-628, 1990. Thomsen, H. S., Bush, Jr., W. H.: Adverse Effects on Contrast Media. Incidence, Prevention and Management. Drug Safety 19: 313 324, 1998). Under these conditions, the examiners for x ray diagnosis in recent years most frequently use non-iodine-containing Gd-chelates instead of the standard triiodoaromatic compounds in computer topography but also in interventional radiology as well as DSA (Gierada, D. S., Bae, K. T.: Gadolinium as CT Contrast Agent: Assessment in a Porcine Model. Radiology 210, 829-834, 1999. Spinosa, D. J., Matsumoto, A. H., Hagspiel, K. D., Angle, J. F., Hartwell, G. D.: Gadolinium-based Contrast Agents in Angiography and Interventional Radiology. AJR 173; 1403-1409, 1999. Spinosa, D. J., Kaufmann, J. A., Hartwell, G. D. : Gadolinium Chelates in Angiography and Interventional Radiology: A Useful Alternative to lodinated Contrast Media for Angiography. Radiology 223, 319-325, 2002). This is, on the one hand, substantiated by the very good compatibility of the metal chelates that are used in MRT, but also by the known fact that lanthanides are also x-ray-opaque. In comparison to iodine, gadolinium and other lanthanides show a greater absorption than iodine especially at higher voltages/energies of the x-ray radiation, such that, in principle, they are suitable as opacifying elements for x-ray diagnosis (Schmitz, S., Wagner, S., Schuhmann-Giampieri, G., Wolf, K. J.: Evaluation of Gadobutrol in a Rabbit Model as a New Lanthanide Contrast Agent for Computer Tomography. Invest. Radiol. 30(1 1): 644-649, 1995). The above-mentioned Gd-containing chelate compounds originally used in the MRT are also readily water-soluble and are distinguished by an excellent compatibility. Compared to the iodine-containing/non-ionic contrast media, the rate of light pseudoallergenic reactions is greatly reduced, the rate of fatal reactions is extremely rare and is indicated with 1/1,000,000 (Runge, V. M.: Safety of Approved MR Contrast Media for Intravenous Injection. J. Magn Reson Imaging 12, 205-213, 2000). In contrast 4 to other contrast medium-induced side effects, such as, e.g., the renal compatibility, pseudoallergic reactions are more likely independent of the administered dose. Also, the smallest dosages can accordingly already trigger a pseudoallergic reaction. Desired are substances that combine the advantages of the two chemically entirely different classes of compounds. The extraordinarily high hydrophilia of the metal chelates suggests a low incompatibility rate.. Iodoaromatic compounds have a higher lipophilia by a factor of 100-200 (larger distribution coefficient between butanol/water) than metal chelates. Based on the low substance concentration and the low specific proportion of the imaging metal in the entire molecule, the previously known metal chelates for x-ray diagnosis are not optimal (Albrecht, T., Dawson, P.: Gadolinium-DTPA as X-Ray Contrast Medium in Clinical Studies. BJR 73, 878-882, 2000). More recent attempts to solve this problem describe the production of metal complex conjugates, in which triiodoaromatic compounds are covalently bonded to an open-chain or macrocyclic metal. complex (US 5,324,503, US 5,403,576, WO 93/16375, WO 00/75141, WO 97/01359, WO 00/71526, US 5,660,814). Because of their low hydrophilia and high viscosity, the latter cannot be administered in adequate concentration and reasonable volumes, however. The purpose is to produce compounds that have an adequate hydrophilia comparable to that of Gd-chelates -- and in addition exhibit a high concentration of opacifying elements. Values that are significantly higher than those in metal chelates, which are approximately 25% (g/g), were desirable. In addition, at a higher concentration, a very good water solubility must be provided. In addition to their good P \WPDOCSjw\Spec 2\12569671 doc.17/01/2008 -5 pharmacological properties, the highly concentrated solutions must also indicate a practical viscosity and a low osmotic pressure. 5 This object is achieved by this invention. The metal complexes of general formula I according to the invention! Hal KA' A'K 15 Hal Hal,
A
2 K in which Hal stands for bromine or iodine, 20 Al stands for the radicals
-CONR'-(CH
2 )n-(CO-CHZ -NH)m-CO-CHZ 2 _*,
-CONR'-(CH
2 )p-(CONR 2
CH
2 )mn-CHOH-CH 2 -*, --CH20-(CH2)p-CHOH-CH2-*,
-CH
2 -0-(CH 2 )n-NRI-(CO-CHZ-NH)m-CO-CHZ 2 -*, or 25 -CH 2 -NRI-CO-(CHZi-NH-CO)m-CHZ 2 ,
A
2 has the same meaning as A' or in the case that A' has the meaning first mentioned above can also stand for the radical -NR -CO-(NR')m
(CH
2
),-NR
2 -(CO-(HZ'-NH)m-CO-CHZ 2 *, 1 2 in which R1 and R , independently of one another, mean a hydrogen 30 atom, a CI-C 2 -alkyl group or a monohydroxy-Ci-C 2 -alkyl group, * designates the binding site to K, Z' and Z 2 , independently of one another, mean a hydrogen atom or a methyl group, 6 n means the numbers 2-4, m means the numbers 0 or I and p means the numbers 1-4, K stands for a macrocyclic compound of formula IA COOX N N N N COOx K (IA) with X in the meaning of a hydrogen atom or a metal ion equivalent of atomic numbers 20-29, 39, 42, 44 or 57-83, provided that at least two X stand for metal ion equivalents and optionally present free carboxy groups optionally are present as salts of organic and/or inorganic bases or amino acids or amino acid amides, show a very good solubility and a distribution coefficient that is comparable to that of Gd-chelates. In addition, the new compounds have a high specific content of opacifying elements, a low viscosity and osmolality and thus good tolerance/compatibility, so that they are extremely well suited as contrast media for x-ray and MR imaging. Hal preferably stands for iodine, R and R2 stand for hydrogen and the methyl group, n stands for the number 2, and p stands for the number 1. By way of example, radicals Al are mentioned: 7
-CONB(CH
2
-)
2 i 3
NHCOCH
2
NHCOCH(C-
3 )-,
-CONH(CH
2
)
2
,
3
NHCOCH
2 -lNHCOCH 2 -,
-CONH(CH?)
2
,
3 NHCOCH,-,
-CONH(CH
2
)
2
,
3
NHCOCH(CH
3 )-,
-GONHCH
2
CH(OH)CH
2 l-,
-CON(CH
3
)CH
2
CH-(OH)CH
2 -, - CH 2
OCH
2 CH(OH)CH,-,
-CONHCH
2
CONHCH
2 C H(OH)CFi 2 -,
-CH
2
NHCOCH
2 -,
-CH
2
NHCOCH(CH
3 )-,
-CH
2
NHCOCH
2
NHCOC'H
2 -,
-CH
2
NHCOCH-
2
NHCOCH(CH
3 )-,
-CH
2
O(CH
2
)
2 NHCOCH:-,
-CON(CH
2
CH
2
OH)CH
2
C.H
2 NIICOCH2-, or
-CH
2
O(CH
2
)
2
N(CH
2
CH
2
OH)COCH
2 -. By way of example, radicals A2 are mentioned:
-NHCOCH
2
NHCOCH
2
NHCOCH(CH
3 )-,
-NHCOCH
2 NHCOC H 2
NHCOCH
2 -, -NHiCOCHNHCOCH 2 -,
-NHCOCH
2
NHCOCH((CH
3 )-,
-N(CH
3
)COCH
2
NHCO('H
2 -,
-NHCONH(CH
2
)
2
NHCONH
2 -, -N14COCH 2
N(CH
2
CH
2 ()H)COCH2-, or 8
-N(CH
3
)COCH
2
N(CH
2
CH
2
OH)COCH
2 -. The compounds of general formula I according to the invention can be produced according to the process that is known by one skilled in the art, by, for example, a) a triiodo- or tribromoaromatic compound of general formula I Y -NHR 1 Hal Hal 0 R NH-Y Y2-NHR Hal being reacted in a way that is known in the art with a macrocyclic compound of general W IN N WV (1ll) formula III in which C'O stands for a -COOH or activated carboxyl group, W stands for a protective group or a -CH 2 COOX' group with X' in the meaning of X or a protective group and -Y'-NR'-CO-B'- stands for the radical A' in the meaning of -CO-NR'-(CH 2
)-NR
2 -(CO-CHZ'-NH)m-CO-CHZ 2 - or -CH 2 -0-(CH2)n-NR -(CO CHZ'-NH)m-CO-CHZ 2 -and -Y 2 -NR'-CO-B'- for Y'-NR'-CO-B'- or for the case that-Y'- 9 NR'-CO-B'- has the meaning first mentioned above, the latter also stands for -NR'-CO (NR' )m(CH 2 )p-NR 2 -(CO-CHZ'-NH)m-CO-CHZ 2 -, whereby B' means the radical on the first or second (viewed from K) carbonyl group between -CO- and K, and Y' or Y2 stands for the deficient radical of the linker group that is reduced by one imino group, and then optionally protective group W being removed and the radical CH 2 COOX being introduced in a way that is known in the art or the protective group that optionally stands for X' being removed and then reacted in a way that is known in the art with a metal oxide or metal salt of an element of atomic numbers 20-29, 39, 42, 44 or 57-83 or b) a triiodo- or tribromoaromatic compound of general formula IV CGO Hal, Hal Hal (IV) being reacted in a way that is known in the art with a macrocyclic compound of general COOX' COOX' R NH-Y 3 -- N N COOx' (V) formula V 10 in which -C'O and X' have the above-mentioned meaning, and -CO-NR'-Y 3 -stands for radical A' in the meaning of -CONR-(CH 2 )p-(CONR 2
CH
2 )m-CH(OH)CH2- and thus Y 3 is in the meaning of -NR'-(CH 2 )p-(CONR 2
CH
2
)-CH(OH)CH
2 -, and then the protective group that optionally stands for X' being removed and then being reacted in a way that is known in the art with a metal oxide or metal salt of an element of atomic numbers 20-29, 39, 42, 44 or 57-83 or c) a triiodo- or tribromoarcimatic compound of general formula VI A Hal, Hal 0 A ' A Ha ( VI) Hal in which A' stands for a radical -- CH 2 -0-(CH 2
),-CH-CH
2 being reacted in a way that is known in the art with a cyclene of general formula VII
~N
H-N N-W'
S(VII)
11 in which W' stands for a hydrogen atom or a protective group, (after the optionally present protective groups have been removed and then radical -CH 2 COOX has been introduced in a way that is known in the art) to form a metal complex of general formula I with A in the meaning of radical -CH 2 -0-(CH 2 )p-CHOH-CH 2 - or d) a triiodo- or tribromoaromatic compound of general formula'VIII
CH
2 -Nucleofug Hal Hal Nucleofug-CH 2
CH
2 -Nucleofug Hal [Nucleofug = nucleofuge] in which nucleofuge stands for a nucleofuge group, being reacted in a way that is known in the art with a macrocyclic compound of general W N R HN-CO-B 2 N N-W N (IX) formula IX in which R' and W have the above-mentioned meanings, and B 2 stands for the radical -(CHZ -NHCO)m-CHZ2- and then being further processed as indicated under a), such that metal complexes of general formula I are obtained with A' in the meaning of radical
-CH
2 -NR'-CO-(CHZ-NHCO)m-CHZ 2 , whereby then optionally in the metal complexes, 12 obtained according to a)-d), of general formula I, still present acid hydrogen atoms are substituted by cations of inorganic or organic bases, amino acids or amino acid amides.
As amino protective groups W, the benzyloxycarbonyl, tert-butoxycarbonyl, trifluoroacetyl, fluorenylmethoxycarbonyl, benzyl, formyl, 4-methoxybenzyl, 2,2,2 trichloroethoxycarbonyl, phthaloyl, 1,2-oxazoline, tosyl, dithiasuccinoyl, allyloxycarbonyl, sulfate, pent-4-enecarbonyl, 2-chloroacetoxymethyl (or ethyl) benzoyl, tetrachlorophthaloyl, and alkyloxycarbonyl groups that are familiar to one skilled in the art can be mentioned [Th. W. Greene, P. G. M. Wuts, Protective Groups in Organic Syntheses, 2nd Ed., John Wiley and Sons (1991), pp. 309 - 385; E. Meinjohanns et al, J. Chem. Soc. Perkin Trans 1, 1995, 405; U. Ellensik et al, Carbohydrate Research 280, 1996, 251; R. Madsen et al, J. Org. Chem: 60, 1995, 7920;-R. R. Schmidt, Tetrahedron Letters 1995, 5343]. Th'e cleavage of the protective groups is carried out according to the process that is known to one skilled in the art (see, e.g., Wfinsch, Methoden der Org. Chemie [Methods of Organic Chemistry], Houben-Weyl, Vol. XV/1, 4 th Edition 1974, p. 315), for example by hydrolysis, hydrogenolysis, alkaline saponification of esters with alkali in aqueous-alcoholic solution at temperatures from 0*C to 50*C, acidic saponification with mineral acids, or in the case of Boc groups with the aid of trifluoroacetic acid. Activated carboxyl groups are defined above as those carboxyl groups that are derivatized, such that they facilitate the reaction with an amine. Which groups can be used for activation is known, and reference can be made to, for example, M. and A. Bodanszky, "The Practice of Peptide Synthesis," Springerverlag 1984. Examples are aducts of carboxylic acid with carbodiimides or activated esters, such as, e.g., hydroxybenzotriazole ester, acid chloride, N-hydroxysuccinimide ester, 13 F F 0
NO
2
-CO
2 \ / NO 2 CO- F ,-COTN , CO2 F F 0
NO
2 and -COS-N% N NN 2 N 4-Nitrophenyl ester and N-hydroxysuccinimide ester are preferred. The activated esters of the above-described compounds are produced as known to one skilled in the art. Also, the reaction with correspondingly derivatized esters of N hydroxysuccinimide, such as, for example: 0 Hal N 0 is possible (Hal halogen). In general, all commonly used activation methods for carboxylic acids that are known in the prior art can be used for this purpose. The activation of carboxylic acid is carried out according to commonly used methods. Examples of suitable activating reagents are dicyclohexylcarbodiimide (DCC), 1 -ethyl-3 -(3 -dimethy laminopropy ) carbodiimide-hydrochloride (EDC), benzotriazol- I -yloxytris(dimethylamino) phosphoniumhexafluorophosphate (BOP) and O-(benzotriazol-1-yl)-l,1,3,3 tetramethyluroniumhexafluorop hosphate (HBTU), preferably DCC. Also, the addition 14 of O-nucleophilic catalysts, such as, e.g., N-hydroxysuccinimide (NHS) or N hydroxybenzotriazole, is possible. Advantageously used as nucleofuges are the radicals: F, CI, Br, I, OTs -OMs, OH F F -O F -O NO2 N N F F 0 * NO 2 O NO0N -O--N
NO
2 If X stands for an acid protective group, lower alkyl, aryl and aralkyl groups, for example the methyl, ethyl, propyl, butyl, phenyl, benzyl, diphenylmethyl, triphenylmethyl, and bis-(p-nitrophenyl)-methyl group, as well as trialkylsilyl groups, are suitable. The t-butyl group and-the benzyl group are preferred. The cleavage of the protective groups is carried out according to the process that is known to one skilled in the art (see, e.g., Wunsch, Methoden der Org. Chemie, Houben-Weyl, Volume XV/1, 4th Edition 1974, p. 315), for example, by hydrolysis, hydrogenolysis, alkaline saponification of esters in aqueous-alcoholic solution at temperatures of 0*C to 50*C, acidic saponification with mineral acids or in the case of tert-butyl esters with the aid of trifluoroacetic acid (Protective Groups in Organic 15 Synthesis, 2 "d Edition, T. W. Greene and P. G. M.Wuts, John Wiley and Sons Inc., New York, 1991). The introduction of the desired metal ions can be carried out as was disclosed in Patents EP 71564, EP 130934 and DE-OS 34 01 052. To this end, the metal oxide or a metal salt (for example,-a chloride, nitrate, acetate, carbonate or sulfate) of the desired element is dissolved or suspended in water and/or a lower alcohol (such as methanol, ethanol, or isopropanol) and reacted with the solution or suspension of the equivalent amount of the complexing agent. The neutralization of optionally still present free carboxy groups is carried out with the aid of inorganic bases (e.g., hydroxides, carbonates or bicarbonates) of, e.g., sodium, potassium, lithium, magnesium or calcium and/or organic bases, such as, i.a., primary, secondary and tertiary amines, such as, e.g., ethanolamine, morpholine, glucamine, N-methyl- and N,N-dimethylglucamine, as well as basic amino acids, such as, e.g., lysine, arginine, and ornithine or amides of original neutral or acidic amino acids. For the production of neutral complex compounds, for example in acidic complex salts in aqueous solution or suspension, enough 6f the desired base can be added to reach the neutral point. The solution that is obtained can then be evaporated to the dry state in a vacuum. It is frequently advantageous to precipitate the neutral salts that are formed by adding water-miscible solvents, such as, e.g., lower alcohols (methanol, ethanol, isopropanol, etc.), lower ketones (acetone, etc.), polar ethers (tetrahydrofuran, dioxane, 1,2-dimethoxyethane, etc.), and thus to obtain easily isolated and readily purified crystallizates. It has proven especially advantageous to add the 16 desired base as early as during the complexing of the reaction mixture and thus to save a process step. The purification of the thus obtained complexes is carried out, optionally after the pH is set to 6 to 8, preferably about 7, by adding an acid or base, preferably by ultrafiltration with membranes of a suitable pore size (e.g., Amicon@YMI, AmiconO YM3), gel filtration on, e.g., suitable Sephadex® gels or by HPLC on silica gel or reverse-phase material. A purification can also be carried out by crystallization from solvents such as methanol, ethanol, i-propanol, acetone or their mixtures with water. In the case of neutral complex compounds; it is frequently advantageous to add the oligomer complexes via an anion exchanger, for example IRA 67 (OH' form), and optionally in addition via a cation exchange, for example IRC 50 (HW form), to separate ionic components. The production of the compounds of general formula I according to the invention can be carried out as indicated above: a) The reaction of triiodo- or tribromoaromatic compounds of general formula II with compounds of general formula III is carried out according to the process of amide formation that is known to one skilled in the art. In this connection, either a direct coupling of the free acid of III with the free amine of II can be performed with dehydrating reagents, such as dicyclohexylcarbodiimide, diisopropylcarbodiimide, EDC; EEDQ, TBTU, or HATU in aprotic solvents such as DMF, DMA, THF, dioxane, toluene, chloroform or methylene chloride at temperatures of 0* - 50*C, or else the acid group is activated in the compound of general formula III, by its first being 17 converted into an active ester (see page 11) and then these esters in a solvent, such as, for example, DMF, DMA, THF, dioxane, dichloromethane, i-ProOH, or toluene, optionally with the addition of an organic or inorganic base, such as NEt 3 , pyridine, DMAP, Hiinig base, Na 2
CO
3 , or CaCO 3 , being reacted at temperatures of -10 to +700 C with the amine of general formula II. In some cases, it has proven advantageous to produce the metal complexes of general formula III directly and to couple their terminal carboxylic acid under the process that is mentioned in WO 98/24775. The production of the metal complexes is described in WO 98/24774. The production of compounds of general formula.II is carried out in the case when Y 2 stands for Y'-by reactions of compounds of general formula IV Co Hal Hal CO CO Hal (IV) with diamines of general formula A
HNR'-(CH
2 )m-NR 2 H (A) in which Hal, CO*, R', R 2 , and m are in the aboVe-indicated meaning, according to the methods of amide formation known to one skilled in the art (see above) in an aprotic solvent such as DMF, DMA, THF, dioxane, 1,2 dichloroethane, chloroform, dichloromethane or toluene, optionally with the 18 addition of an organic or inorganic base, such as NEt 3 , pyridine, DMAP, Htinig base, Na 2
CO
3 , K 2
CO
3 , or CaCO 3 , at temperatures of 0 0 C - 100'C. In many cases, it has proven advantageous to use diamine itself as a solvent. Many times, it may be advantageous to use one of the two terminal amino groups in protected form (e.g., Mono-Boc, Mono-Z) and, after coupling is completed, to cleave this protective group according to the methods known to one skilled in the art (T. W.. Greene, see above). The diamines or mono-protected diamines are known in the literature. and can be purchased (e.g., Aldrich, Fluka). The acid chloride of the compound of general formula IV is preferably used. The production of the compound COCl CIOC COCl is described in DE 3001292. The production of the corresponding ti-bromine compound is carried out analogously from tribromoaminoisophthalic acid by Sandmeyer reaction (introduction of CN and subsequent saponification) as described in EP 0073715. In the case that Y2 is not equal to Y1, the following procedure has proven worthwhile: 19 The compounds of general formula B CO Hal Hal *0C NH2 Hal (B) in which CO* and Hal are in the above-mentioned meaning, are first reacted with compounds of general formula C CO*-(CHZ')-NH-Sg (C) in which CO* and Z' have the above-mentioned meaning, and Sg stands for an amino protective group. The reaction is carried out according to the methods of amide formation that are already indicated above (Neher et al, Helv. Chim. Acta, 1946, 1815.) Then, as already described above, it is reacted with compounds of general formula A and then optionally present amino protective groups are cleaved (see T. W. Greene). It has proven advantageous to use the acid chlorides of general formula C. If Sg represents a trifluoroacetyl protective group, the latter is cleaved directly in a single-pot process with excess diamine of general formula A. Compounds of general formula C can be obtained according to methods that are known in the literature. For the production of urea derivatives, compounds of general formula B are first reacted with isocyanates of general formula D -(R) O=C=N-(CH2)m-N-Sg (D) 20 and then further reacted as described above with the diamines of the general formula. The reaction of the isocyanates is carried out in aprotic solvents as described above for amide formation. The reaction temperature is 0*C to 100*C. Isocyanates (D) are produced as described in, e.g., Guichard et al., J. Org. Chem., 1999, 8702. Compounds of general formula B are described in DE 3001292. b) The reaction of compounds of general formula IV with compounds of general formula V is carried out according to the methods of amide formation that are known to one skilled in the art, as were already previously described in detail under a). Also here, the acid chloride of compounds IV is preferably used. Compounds of general formula V are obtained from compounds of COOX N" /coox, HN N N coox' (E) general formula E in which X' is in the above-mentioned meaning, by reaction with primary 21 epoxides of general formula F 0 2/ \ R1 N'-(CH 2 )p-(CONR 2 )M-CH-CH2 (F) Sg in which R1, Sg, p, m, and R2 are in the above-mentioned meanings. The reaction is carried out in protic or aprotic solvents, such as methanol, ethanol, butanol, propanol, DMF, toluene, CHCl 3 , or DMA (optionally in each case with the addition of water) at temperatures of 0 0 C to 15*C. In some cases, the addition of a Lewis acid, such as LiCl, LiBr, LiJ, LiClO 4 or Y(triflate) 3 , has proven worthwhile. Compounds of general formula F are accessible according to methods that are known in the literature (Krawiecka et al., J. Chem. Soc. Perkin Trans. 1, _2001, 1086) or can be purchased. Compounds of general formula E are so-called DO3A derivatives and are described in the literature (Chatal et al., Tetrahedron Lett., 1996, 7515). c) The reaction of epoxides of general formula VI with compounds of general formula VII is carried out according to the methods of the reaction of epoxides with amines that are described under b). In some cases, it has proven advantageous to use the method described in EP 0545511 with use of the compound 22 N N NH N Action can also be taken, however, according to EP 0643705, or the lithium process that is described under WO 98/55467 can be used. The production of compounds VI in the case of the W'-protective group, see b), is known in the literature. The TriBoc-cyclene compound is described in Kimura et al., J. Am. Chem. Soc., 1997, 3068, and the tri Z-cyclene compound is described in Delaney et al., J. Chem. Soc., Perkin Trans., 1991, 3329. Compounds of general formula VI are accessible by reaction of triols of general formula G Hal HO OH Hal Hal (G)
OH
23 with epoxides of general formula H 0 Z -(OH2)p-CH-CH 2 (H) with p in the above-mentioned meaning and in which Z stands for Cl, Br, I, or. OT. The reaction is carried out according to methods of glycide ether formation (p=1) or etherification that are known in the literature, Mouzin et al., Synthesis, 1983, 117. Compounds of general formula H are known in the literature, e.g., Sharpless et al., J. Org. Chem., and DE 935433 or can be purchased (e.g., epichlorohydrin, Fluka, Aldrich). Compounds of general formula G in the case of Hal=iodine are described in US 6,310,243. The production of the bromine compound is carried out analogously. d) The reaction is carried out such that first the aide of the compounds of general formula IX is deprotonated according to the method that is known to one skilled in the art, e.g., with NaH in DMF, THF, DMA, dioxane, toluene (temperatures of 0*C - 100*C) or BuLi, LDA, Li-HMDS, Na-HMDS in THF, MTB at temperatures of -70' to 0 0 C and then reacted with compounds of general formula VIII (preferred temperatures of-70 to 70'C). Compounds of general formula VIII are obtained from compounds of general formula G 24 Hal HO OH Hal Hal (G) OH according to the methods that are known to one skilled in the art for converting a primary OH group into a halide or tosylate, triflate, etc. Compounds of general formula IX are obtained from compounds of general formula IXa W N *CO -B2- N N-W N IX a W by amide formation with amines of formula R NH 2 (amides of the formula are commercially available or known in the literature) according to the methods of amide coupling already mentioned under a). Compounds of general formula IXa are described in, e.g., WO 97/02051, WO 99/16757 or can be produced simply from tri-Boc cyclene or tri-Z-cyclene according to methods that are known in the literature. The compounds according to the invention can be used both in x-ray diagnosis and in MR diagnosis. The high x-ray opacity paired with the good water-solubility of the 25 iodized x-ray contrast media is combined with the intense hydrophilia of metal chelates and good compatibility in a molecule that is inherent in them. The very high hydrophilia of the new compounds results in that the side-effect profile corresponds to that of the very well-tolerated Gd compounds, as they are used in MR imaging. This property therefore makes it especially suitable for use in patients with a proven allergy to iodized compounds or in the case of existing atopy. In particular, the incidence of severe side effects such as bronchiospasms and shock or even death is reduced to the low level of the MR contrast medium. The low osmotality of the formulations is an indication of a generally very good compatibility of the new compounds. They are therefore especially suitable for intravascular (parenteral) uses. Depending on the pharmaceutical formulation, the contrast media can be used exclusively for x-ray diagnosis (triiodine complexes with diamagnetic metals), but also simultaneously for x-ray diagnosis and MRT diagnosis (triiodine complexes with paramagnetic atoms, preferably Gd). The compounds can very advantageously be used in, e.g., urography, computer tomography, angiography, gastrography, mammography, cardiology and neuroradiology. Even in the case of radiation therapy, the complexes that are used are advantageous. The compounds are suitable for all perfusion measurements. A differentiation of areas that are well supplied with blood and ischemic areas is - possible after intravascular injection. Quite generally, these compounds can be used in all indications where conventional contrast media are used in x-ray diagnosis or MR diagnosis.
26 The new contrast media can also be used for the magnetization-transfer technique (see, e.g., Journ. Chem. Phys. 39(11), 2892 (1963), as well as WO 03/013616), if they contain mobile protons in their chemical structure. This is the case, for example, in the hydroxyl group-containing compounds, as they are described in Example 5 (page 41), Example 6 (page 44), Example 7 (page 47) and Example 8 (page 50).- This application document thus also comprises contrast media that are suitable in principle for this special MRI technique. The contrasting of cerebral infarctions and tumors of the liver or space-occupying processes in the liver as well as of tumors of the abdomen (including the kidneys) and the muscle-skeleton system is especially valuable diagnostically. Based on the low osmotic pressure, the blood vessels can be visualized especially advantageously after intraarterial or else intravenous injection. If the compound according to the invention is intended for use in MR diagnosis, the metal ion of the signaling group must be paramagnetic. These are in particular the divalent and trivalent ions of the elements of atomic numbers 21-29, 42, 44 and 58-70. Suitable ions are, for example, the chronium(III), iron(II), cobalt(II), nickel(II), copper(II), praseodymium(III), nodymium(III), samarium(III) and ytterbium(III) ion. Because of their strong magnetic moment, gadolinium(III), terbium(III), dysprosium(III), holmium(III), erbium(III), iron(III) and manganese(II) ions are preferred; gadolinium(III) and manganesle(II) ions are especially preferred. If the compound according to the invention is intended for use in x-ray diagnosis, the metal ion is preferably derived from an element of a higher atomic number to achieve an adequate absorption of the x-rays. It was found that for this purpose, diagnostic 27 agents that contain a physiologically compatible complex salt with metal ions of elements of atomic numbers 25, 26 and 39 as well as 57-83 are suitable. Preferred are manganese(II), iron(II), iron(III), prasecdymium(III), neodymium(III), samarium(III), gadolinium(III), ytterbium(III) or bismuth(III) ions, especially dysprosium(III) ions and yttrium(III) ions. The production of the pharmaceutical agents according to the invention is carried out in a way that is known in the art by the complex compounds according to the invention - optionally with the addition of the additives that are commonly used in galenicals - being suspended or dissolved in aqueous medium and then the suspension or solution optionally being sterilized. Suitable additives are, for example, physiologically harmless buffers (such as, for example, tromethamine), additives of complexi'ng agents or weak complexes (such as, for example, diethylenetriaminepenta acetic acid or the Ca complexes that correspond to the metal complexes according to the invention) or - if necessary - electrolytes such as, for example, sodium chloride, or - if necessary - antioxidants, such as, for example, ascorbic acid. If suspensions or solutions of the agents according to the invention in water or physiological salt solution are desired for enteral or parenteral administration or other purposes, they are mixed with one or more adjuvant(s) that are commonly used in galenicals [for example, methyl cellulose, lactose, mannitol] and/or surfactant(s) [for example, lecithins, Tween*, Myrj*] and/or flavoring substance(s) for taste correction [for example, ethereal oils]. In principle, it is also possible to produce the pharmaceutical agents according to the invention without isolating the complexes. In any case, special care must be taken to 28 perform the chelation so that the complexes according to the invention are virtually free of noncomplexed metal ions that have a toxic effect. This can be ensured, for example, with the aid of color indicators such as xylenol orange by control titrations during the production process. The invention therefore also relates to the process for the production of complex compounds and their salts. As a final precaution, there remains purification of the isolated complex. In the in-vivo administration of the agents according to the invention, the latter can be administered together with a suitable vehicle, such as, for example, serum or physiological common salt solution, and together with another protein, such as, for example, human serum albumin (HSA). The agents according to the invention are usually administered parenterally, preferably i.v. They can also be administered intraarterially or interstitially/ intracutaneously, depending on whether a vessel/organ is to be visualized selectively contrasted (e.g., visualization of the coronary arteries after intraarterial injection) or tissue or pathologies (e.g., diagnosis of cerebral tumors after intravenous injection). The pharmaceutical agents according to the invention contain preferably 0.001 1 mol/l of the above-mentioned compound and are generally dosed in amounts of 0.001 5 mmol/kg. The agents according to the invention meet the many requirements for suitability as contrast media for magnetic resonance tomography. After oral or parenteral administration by increasing the signal intensity, they are extremely well suited for enhancing the informational value of the image that is obtained with the aid of an MR tomograph. They also show the high effectiveness that is necessary to load the body with the minimum possible amounts of foreign substances and the good compatibility 29 that is necessary to maintain the non-invasive nature of the studies. The high effectiveness (relaxivity) of the paramagnetic compounds according to the invention is of great advantage for use in magnetic resonance tomography. Thus, the relaxivity (L/mmol~'sec-' of gadolinium-containing compounds is generally 2 to 4x greater than in conventional Gd complexes (e.g., gadobutrol). The good water solubility and low osmolality of the agents according to the invention makes it possible to produce highly concentrated solutions, so as to keep the volume burden of the circulatory system within reasonable limits and to offset the dilution by bodily fluids. In addition, the agents according to the invention exhibit not only high stability in-vitro, but also surprisingly high stability in-vivo, so that a release or an exchange of the ions, which are inherently toxic and are bonded in the complexes, is carried out only extremely slowly within the time that it takes for the new contrast media to be completely excreted. In general, the agents according to the invention are dosed for use as MRT diagnostic agents in amounts of -0.001-5 mmol of Gd/kg, preferably 0.005 - 0.5 mmol of Gd/kg. The agents according to the invention are extremely well suited as x-ray contrast media, whereby it is especially to be emphasized that with them, no signs of the anaphylaxis-like reactions that are known from the iodine-containing contrast media can be detected in biochemical-pharmacological studies. In the case of strong x-ray absorption, they are especially effective in areas of higher tube voltages (e.g., CT and DSA). In general, the agents according to the invention are dosed for administration as x-ray contrast media analogously to, for example, meglumine-diatrizoate, in amounts of 30 0.01 - 5 mmol/kg, preferably 0.02 - 1 mmol of substance/kg, which corresponds to 0.06 6 mmol (I+Dy)/kg in the case of e.g., iodine-Dy compounds. Depending on the diagnostic requirement, formulations can be selected that can be used both in x-ray diagnosis and in MR diagnosis. To achieve optimal results for both imaging modalities, it may be advantageous to select formulations in which the proportion of paramagnetic ions is reduced, since for many MR diagnostic applications, a point of diminishing returns is reached with too high a proportion of paramagnetic ions. For dual uses, formulations can be used in which the proportion, in percent, of paramagnetic substances (e.g., Gd) is reduced to 0.05 to 50, preferably to 2-20%. As an example, a cardiac diagnostic application can be mentioned. For the examination, a formulation that consists of the substances according to the invention in a total concentration of, e.g., 0.25 mol/1 is used. The proportion of Gd-containing complexes is 20%, the remaining 80% of the metals are, e.g., Dy atoms. In an x-ray coronary angiography after intra-arterial or intravenous administration, e.g., 50 ml is used, i.e., 0.18 mmol of substance per kg of body weight in a patient who weighs 70 kg. Shortly after x-ray visualization of the coronary vessels has taken place, an MR diagnosis of the heart is followed to be able to differentiate vital myocardial areas from necrotic myocardial areas. The amount of about 110 pmol of Gd/kg previously administered for the test is optimal for this purpose.
31 Example 1 a) 1,3, 5-Triiodotrimesic acid-NN,N-tris-(2-aminoethyl)amide A solution of 10 g (15.5 mmol) of 1,3,5-triiodotrimesic acid trichloride (DE 3001292, Schering AG, priority: 1/11/1980) in 100 ml of tetrahydrofuran is added in drops to 24 g (400 mmol) of ethylenediamine for 1 hour at room temperature and stirred for 14 more hours. The solid that accumulates is filtered off, rewashed with ethanol, taken up in 100 ml of water, and the solution that is produced is set at a pH of 8.0 with 1 M lithium hydroxide solution. After concentration by evaporation in a vacuum, it is recrystallized from ethanol. Yield: 7.8 g (70% of theory) of a colorless solid Elementary analysis: Cld.: C 25.23 H 2.96 N 11.77 I 53.31 Fnd.: C 25.46 H 2.99 N 11.68 I 52.98 b) 1,3 ,5-Triiodotrimesic acid-N,N,N-tris-(3,6-diaza-4,7-dioxo-8-methyloctane-1,8 diyl- { 10-[ 1,4,7-tris-(carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex] })amide .48.5 g (77.09 mmol) of the Gd complex of 10-[4-carboxy-1-methyl-2-oxo-3 azabutyl]- 1,4,7,1 0-tetraazacyclododecane- 1,4,7-triacetic acid (WO 98/24775, Schering AG, (Example 1)) is suspended in 400 ml of DMSO and mixed with 9.8 g (84.8 mmol) of N-hydroxysuccinimide and 16.7 g (81 mmol) of dicyclohexylcarbodiimide and preactivated for 1 hour. Then, it is mixed with 12.3 g (17.12 mmol) of 1,3,5 triiodotrimesic acid-N,N,N-tris-(2-aminoethyl)-amide and stirred for 3 days at room temperature under nitrogen. Insoluble components are filtered out, and the solution is 32 poured into 2000 ml of acetone. The solid that accumulates in this case is filtered off and washed in portions with 1000 ml of acetone and with 500 ml of diethyl ether. The residue is taken up in 500 ml of water and absorptively precipitated for 2 hours with 100 g of ion exchanger (IRA 67 OH-form) and filtered off. Then, it is absorptively precipitated for 2 hours with 30 g of ion exchanger (IR 267 H-form), filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off, and the solution is concentrated by evaporation to 100 ml. To remove the residual dimethyl sulfoxide, the solution is poured into 1000 ml of acetone, and the precipitate that accumulates is filtered off. The residue is dissolved in 250 ml of water, and with a little ion exchanger (H-form and OH-form), the conductivity is set at, a value of 0.005 mS (pH = 7.0), filtered off and concentrated by evaporation in a vacuum. Yield: 33.9 g (73% of theory) of a colorless solid Water content (Karl-Fischer): 5.9% Elementary analysis (relative to the anhydrous substance): Cld..: C 33.92 H 4.15 N 11.54 114.93 Gd 18.51 Fnd.: C 33.99 H-4.17 N 11.49 114.88 Gd 18.37 Example 2 1,3,5-Triiodotrimesic acid-NN,N-tris-(3,6-diaza-4,7-dioxooctane-1,8-diyl-{10-[1,4,7 tris-(carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex] })amide 9.4 g (15.3 mmol) of the Gd complex of 10-[4-carboxy-2-oxo-3-azabutyl] 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (WO 98/24775, Schering AG, (Example 11)) is suspended in 100 ml of DMSO and mixed with 1.96 g (17 mmol) of N hydroxysuccinimide and 3.3 g (16 mmol) of dicyclohexylcarbodiimide and reactivated 33 for 1 hour. -Then, it is mixed with 2.4 g (3.36 mmol) of 1,3,5-triiodotrimesic acid N,N,N-tris-(2-aminoethyl)-amide and stirred for 3 days at room temperature under nitrogen. Insoluble components are filtered out, and the solution is poured into 1000 ml of acetone. The solid that accumulates in this case is filtered off and washed in portions with 300 ml of acetone and with 100 ml of diethyl ether. The residue is taken up in 200 ml of water and absorptively precipitated for 2 hours with 30 g of ion exchanger (IRA 67 OH-form) and filtered off. Then, it is absorptively precipitated for 2 hours with 10 g of ion exchanger (IR 267 H-form), filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off, and the solution is concentrated by evaporation to 100 ml. To remove the residual dimethyl sulfoxide, the solution is poured into 1000 ml of acetone, and the precipitate that accumulates is filtered off. The residue is dissolved in 250 ml of water, and with a little ion exchanger (H-form and OH-form), the conductivity is set to a value of 0.005 mS (pH = 7.0), filtered off and concentrated by evaporation in a vacuum. Yield: 6.0 g (68% of theory) of a colorless solid Water content (Karl-Fischer): 5.4% Elementary. analysis (relative to the anhydrous substance): Cld.: C 33.06 H 3.98 N 11.73 115.18 Gd 18.82 Fnd.: C33.31 H4.02 N11.70 115.09 Gd'18.74 34 Example 3 a) 1,4,7-Tris-(benzyloxycarbonyl)-1 0-(ethoxycarbonylmethyl) 1,4,7,10 tetrazacyclododecane 68.2 g (118.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10 tetrazacyclododecane (Delaney et al. , J Chem. Soc. Perkin Trans. 1991, 3329) is dissolved in 700 ml of acetonitrile and mixed with 75.4 g (545.5 mmol) of sodium carbonate. Then, 39.6 g (355.5 mmol) of bromoacetic acid ethyl ester is added while being stirred vigorously, and it is heated for 20 hours to 40'C. Insoluble components are filtered out, evaporated to the dry state and chromatographed on silica gel (mobile solvent: ethyl acetate/hexane 20 :.1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 72.3 g (92% of theory) of a colorless oil Elementary analysis: Cld.: C 65.44 H 6.71 N 8.48 Fnd.: C 65.51 H 6.78 N 8.43 b) 1,4,7-Tris-(benzyloxycarbonyl)-10-(carboxymethyl)-1,4,7,10 tetrazacyclododecane 34 g (51.4 mmol) of 1,4,7-tris-(berizyloxycarbonyl)-10-(ethoxycarbonylmethyl) 1,4,7,10-tetrazacyclododecane is dissolved in 300 ml of dioxane and mixed with 144 ml of 5% aqueous NaOH solution and stirred for 24 hours at room temperature. After neutralization with concentrated HCl, it is evaporated to the dry state. The residue is taken up in 250 ml of ethyl acetate and extracted twice with 250 ml each of IN HCl 35 solution. The organic phase is dried on sodium sulfate, and the solvent is evaporated to the dry state. Yield: 27.8 g (85% of theory) of a colorless solid Elementary analysis: Cld.: C 64.54 H 6.37 N 8.86 Fnd.: C 64.47 H 6.41 N 8.79 c) 1,3,5-Triiodotrimesic acid-NN,N-tris-(3-aza-4-oxopentane-1,5-diyl-{10-[1,4,7 tris-(benzyloxycarbonyl)-1,4,7,10-tetrazacyclododecanyl]})-amide 44.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-10-(carboxymethyl) 1,4,7,10-tetrazacyclododecane, 21 ml (164 mmol) of triethylamine, 14.6 g (70.5 mmol) of dicyclohexylcarbodiimide and 8.1 g (70.5 mmol) ofN-hydroxysuccinimide are added to a suspension of 16.8 g (23.5 mmol) of 1,3,5-triiodotrimesic acid-NN,N-tris-(2 aminoethyl)amide in 446 ml of DMF, and it is stirred for 20 hours at room temperature. Insoluble components.are filtered out, and it is evaporated to the dry state. The residue is taken up-in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/ methanol 20: 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 23.3 g (39% of theory) of a colorless solid Elementary analysis: Cld.: C 54.93 H 5.32 N 9.86 114.88 Fnd.: C55.11 H5.37 N9.81 114.76 36 d) 1,3,5-Triiodotrimesic acid-NN,N-tris-(3-aza-4-oxopentane-1,5-diyl-{1-[1,4,7,10 tetrazacyclododecanyl]})-amide 20 g (7.8 mmol) of 1 ,3,5-triiodotrimesic acid N,N,N-tris-(3-aza-4-oxopentane 1,5-diyl-{ 10-[1,4,7-tris-(benzyloxycarbonyl)-1,4,7,1 -tetrazacyclododecanyl]} )-amide is mixed at 0-5*C carefully [with] 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is pot red into 800 ml of diethyl ether, and the solid that accumulates in this case is suctioned off and rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane and, while being stirred vigorously 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separate , the aqueous phase is extracted three times with 50 ml each of dichloromethane, the ombined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 10.3 g (97% of theory) of a colorless olid Elementary analysis: Cld.: C 40.01 H 6.04, N 18.66 128.18 Fnd.: C 40.19 H 6.07 N 18.60 128.11 e) 2,4,6-Triiodotrimesic acid-NN,N-tris-(3-aza-4-oxopentane-1,5-diyl-{10-[1,4,7 tris-(carboxymethyl)-1,4,7,10-tetrazacyclodoc ecanyl]})-amide 18.6 g (13.7 mmol) of 1,3,5-triiodotrimesic ac id-N,N,N-tris-(3-aza-4-oxopentane 1,5-diyl-{ 1-[1,4,7,1 0-tetrazacyclododecanyl]})-amide is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60'C with 32% NaOH. It is heated for 10 hours to 70*C, where y the pH of the reaction mixture is 37 readjusted continuously to 9.5. After cooling to room temperature, a pH of I is set with concentrated HCl, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 13.8 g (54% of theory) of a colorless solid Elementary analysis: CILd.: C 40.39 H 5.33 N 13.46 I 20.32 Fnd.: C 40.51 H 5.39 N 13.38 120.36 f) 2,4,6-Triiodotrimesic acid-NN,N-tris-(3-aza-4-oxopentane-1,5-diyl-{ 10-[1,4,7 tris-(carboxylatomethyl)- 1,4,7,1 0-tetrazacyclododecanyl, Gd complex] })amide 13 g (6.9 mmol) of 2,4,6-triiodotrimesic acid-NN,N-tris-(3-aza-4-oxopentane 1,5-diyl-{l0-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetrazacyclododecanyl]})-amide is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, a pH of 7.4 is set with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion 38 exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 6.2 g (36% of theory) of a colorless solid Water content (Karl-Fischer): 6.2% Elementary analysis (relative to the anhydrous substance): Cld.: C 32.39 H 3.88 N 10.79 116.30 Gd 20.20 Fnd.: C 32.44 H 3.89 N 10.71 116.33 Gd 20.07 g) 2,4,6-Triiodotrimesic acid-N,N,N-tris-(3-aza-4-oxopentane-1,5-diyl-{10-[1,4,7 tris-(carboxylatomethyl)- 1,4,7,1 0-tetrazacyclododecanyl, Dy complex]})amide 13.g (6.9 mmol) of 2,4,6-triiodotrimesic acid-N,N,N-tris-(3-aza-4-oxopentane - 1,5-diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetrazacyclododecanyl]})-amide is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.88 g (10.4 mmol) of dysprosium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that - contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze-dried. Yield: 7.0 g (41% of theory) of a colorless solid Water content (Karl-Fischer): 5.9% 39 Elementary analysis (relative to the anhydrous substance): Cld.: C 32.18 H 3.86 N 10.72 116.19 Dy 20.73 Fnd.: C 32.32 H 3.91 N 10.67 116.11 Dy 20.68 h) 2,4,6-Triiodotrimesic acid-NN,N-tris-(3-aza-4-oxopentane-1,5-diyl-{10-[1,4,7 tris-(carboxylatomethyi)- 1,4,7,1 0-tetrazacyclododecanyl, Y complex]))amide 13 g (6.9 mmol) of 2,4,6-triiodotrimesic acid-NNN-tris-(3-aza-4-oxopentane 1,5-diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetrazacyclododecanyl]})-amide is dissolved in 100 ml of water and acidified by adding-3 ml of acetic-acid. 3.72 g (10:4 mmol) of yttrium carbonate.is added, and it is refluxed for 6 hours. After the complexing is completed, it is set at pH 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 6.5 g (42% of theory) of a colorless solid Water content (Karl-Fischer): 4.8% Elementary analysis (relative to the anhydrous substance): Cld.: C 35.51 H 4.26 N 11.38 I 17.87 Y 12.52 Fnd.: C35.73 H4.31 N11.31 1.17.79 Y12.60 40 Example 4 a) 1,4,7-Tris-(benzyloxycarbonyl)- 1 0-(1 -ethoxycarbonylethyl)- 1,4,7,10 tetrazacyclododecane 50.1 g (87.0 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10 tetrazacyclododecane (Delaney et al. , J Chem Soc. Perkin Trans. 1991, 3329) is dissolved in 500 ml of acetonitrile and mixed with 55.5 g (400 mmol) of sodium carbonate. Then, while being stirred- vigorously, 54.3 g (300 mmol) of 1 bromopropionic acid ethyl ester is added, and it is heated for 20 hours to 60'C. Insoluble components are filtered out, evaporated to the dry state and chromatographed on silica gel (mobile solvent: ethyl acetate/hexane 20 :1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 46 g (78% of theory) of a colorless oil. Elementary analysis: Cld.: C 65.86 H 6.87 N 8.30 Fnd.: C 65.99 H 6.88 N 8.23 b) 1,4,7-Tris-(benzyloxycarbonyl)-1 0-(1 -carboxyethyl)- 1,4,7,10 tetrazacyclododecane' 33.7 g (50 mmol),of 1,4,7-tris-(benzyloxycarbonyl)-10-(1-ethoxycarbonylethyl) 1,4,7,10-tetrazacyclododecane is dissolved [in] 300 ml of dioxane and mixed with 140 ml of 5% aqueous NaOH solution and stirred for 24 hours at room temperature. After neutralization with concentrated HCl, it is evaporated to the dry state. The residue is taken up in 250 ml of ethyl acetate and extracted twice with 250 ml each of 1N HCL 41 solution. The organic phase is dried on sodium sulfate, and the solvent is evaporated to the dry state. Yield: 28.2 g (87% of theory) of a colorless solid Elementary analysis: Cld.: C 65.00 H 6.55 N 8.66 Fnd.: C 65.22 H 6.59 N 8.60 c) 1,3,5-Triiodotrimesic acid-NN,N-tris-(3-aza-1-methyl-4-oxopentane-1,5-diyl (10-[1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10-tetrazacyclododecanyl]})-amide 45.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)- 1 0-(1 -carboxyethyl) 1,4,7,10-tetrazacyclododecane, 21 ml (164 mmol) of triethylamine, 14.6 g ( 70.5 mmol) of dicyclohexylcarbodiimide and 8.1 g (70.5 mmol) of N-hydroxysuccinimide are added to a suspension of 16.8 g (23.5 mmol) of 1,3,5-triiodotrimesic acid-N,N,N-tris-(2 aminoethyl)amide in 450 ml DMF, and it is stirred for 20 hours at room temperature. Insoluble components are filtered out and evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20: 1): The fractions that contain the product are combined and concentrated by evaporation. Yield: 24.5 g (40% of theory) of a colorless solid Elementary analysis: Cld.: C 55.43 H 5.47 N 9.70 114.64 Fnd.: C 55.49 H 5.43 N 9.66 114.60 42 d) 1,3,5-Triiodotrimesic acid-NN,N-tris-(3-aza-1-methyl-4-oxopentane-1,5-diyl-{1 [1,4,7,10-tetrazacyclododecanyl]})-amide 23 g (8.85 mmol) of 1,3,5-triiodotrimesic acid-N,N,N-tris-(3-aza-4-oxopentane 1,5-diyl-{10-[1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10-tetrazacyclododecanyl]})-amide is mixed carefully at 0-5'C with 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 ml of diethyl ether; the solid that accumulates in this case is suctioned off and.rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 11.7 g (95% of theory) of a colorless solid Elementary analysis: Cld.: C41.39 H6.29 N18.10 127.33 Fnd.: C41.51 H6.32 N 18.01 127.26 e) 2,4,6-Triiodotrimesic acid-N,N,N-tris-(3-aza-1-methyl-4-oxopentane-1,5-diyl {10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetrazacyclododecanyl]})-amide 18.8 g (13.5 mmol) of 1,3,5-triiodotrimesic acid-N,N,N-tris-(3-aza-1-methyl-4 oxopentane- 1,5-diyl-{ 1-[1,4,7,1 0-tetrazacyclododecanyl]})-amide is dissolved in 75 ml ,of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60'C with 32% NaOH. It is heated for 10 hours to 70'C, whereby the pH of the reaction 43 mixture is continuously readjusted to 9.5. After cooling to room temperature, a pH of 1 is set with concentrated HCl, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H+-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in-this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 15.0 g (58% of theory) of a colorless solid Elementary analysis: Cid.: C 41.39 H 5.53 N 13.16 119.88 Fnd.: C 41.46 H 5.537 N 13.11 119.79 f) 2,4,6-Triiodotrimesic acid-NN,N-tris-(3-aza-1-methyl-4-oxopentane-1,5-diyl {10-[1,4,7-tris-(carboxylatomethyl)- 1,4,7,1 0-tetrazacyclododecanyl, Gd complex]})amide 13.2 g (6.9 mmol) of 2,4,6-triiodotrimesic acid-N,N,N-tris-(3-aza-1-methyl-4 oxopentane-1,5-diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetrazacyclododecanyl]}) amide is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10:4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g 44 of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then it is absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze dried. Yield: 7.1 g (41% of theory) of a colorless solid Water content (Karl-Fischer): 5.6% Elementary analysis (relative to the anhydrous substance): Cld.: C 33.34 H 4.07 N 10.60 1 16.01 Gd 19.84 Fnd.: C 33.51 H 4.14 N 10.53 1 15.98 Gd 1.9.76 Example 5 a) Dibenzyloxiranylmethylamine 98.6 g (0.5 mol) of dibenzylamine and 55.5 g (0.6 mol) of epichlorohydrin are dissolved in 500 ml of methanol and heated for 6 hours to 80*C. The solution is evaporated to the dry state and mixed with 500 ml of tert-butanol. A solution of 36.4 g (0.65 mol) of potassium hydroxide in 50 ml of water is now added while being stirred, and it is heated for 2 hours to 80*C. After cooling to room temperature, the potassium chloride that is formed is filtered out, the filtrate is evaporated to the dry state and chromatographed on silica gel (mobile solvent: hexane/ethyl acetate 10 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 126 g (99% of theory) of a colorless oil Elementary analysis: Cld.: C 80.60 H 7.56 N 5.53 Fnd.: C 80.72 H 7.59 N 5.51 45 b) [1 -(3-Dibenzylamino-2-hydroxypropyl- 1,4,7,1 0-tetraazacyclododecane] pentahydrochloride 100 ml (752.77 mmol) of NN-dimethylformamide dimethyl acetal is added to 100 g (580.48 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 700 ml of toluene, and it is heated for 2 hours to 120*C under nitrogen. In this case, a methanol/toluene azeotrope is distilled off continuously. Then, the reaction mixture is concentrated by evaporation at 70*C in a vacuum, 157 g (620 mmol) of dibenzyloxiranylmethylamine is added, and it is heated under nitrogen for 24 hours to 1 10 C. After cooling to room temperature, it is mixed with 500 ml of water and extracted twice with 200 ml each of ethyl acetate. The aqueous phase is mixed with 250 ml of concentrated HCl and then.. heated for 12 hours to 80'C. It is evaporated to the dry state, mixed with 200 ml of ethanol and 200 ml of methanol and evaporated again to the dry state. The residue is dissolved in 600 ml of ethanol while being heated, and then it is slowly cooled to 0 0 C, whereby a white solid is crystallized out. The solid is filtered off, washed with ethanol and then dried at 50'C in a vacuum. Yield: 280 g (79% of theory) of a colorless solid Elementary analysis: Cld.: C 49.39 H 7.29 N 11.52 Cl 29.16 Fn'd.: C 49.67 H 7.44 N 11.56 Cl 28.22 c) 10-(3-Dibenzylamino-2-hydroxypropyl)-1,4,7-tris-(tert-butoxycarbonylmethyl) 1,4,7,1 0-tetraazacyclododecane 32% NaOH solution is added to 250 g (411.2 mmol) of [1-(3-dibenzylamino-2 hydroxypropyl)-1,4,7,10-tetraazacyclododecane] pentahydrochloride, dissolved in 46 500 ml of water and 500 ml of dichloromethane, while being stirred vigorously until a pH of 10 is- reached. The organic phase is separated, the aqueous phase is extracted three times with 250 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. The residue is dissolved in 1200 ml of acetonitrile and mixed with 176.2 g (1.275 mol) of potassium carbonate. Then, 248.7 g (1.275 mol) of bromoacetic acid-tert-butyl ester is added while being stirred vigorously, and it is heated for 3 hours to 60'C. Insoluble components are filtered out, it is evaporated to the dry state and chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20: 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 262 g (83% of theory) of a colorless solid Elementary analysis: Cld.: C 67.25 H 9.05 N 9.12 Fnd.: C 67.33 H 9.02 N 9.15 d) 10-(3 -Amino-2-hydroxypropyl)-1,4,7-tris-(tert-butoxycarbonylmethyl)-acyclo dodecane 76.8 g (100 mmol) of 10-(3-dibenzylamino-2-hydroxypropyl)- 1,4,7-tris-(tert butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane is dissolved in 500 ml of methanol, mixed with 40 ml of water, and 10 g of palladium catalyst (20% Pd/C) is added. It is hydrogenated for 8 hours at 50'C under normal pressure. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum. Yield: 58.5 g (quantitative) of a colorless powder 47 Elementary analysis: Cld.: C 59.26 H 9.77 N 11.91 Fnd.: C 59.48 H 9.86 N 11.67 *e) 1,3,5-Triiodotrimesic acid-NNN-tris-(2-hydroxypropane-1,3-diyl-{ 10-[1,4,7 tris-(tert-butoxycarbonylmethyl)- 1,4,7,1 0-tetraazacyclododecanyl]})amide 12.2 g (120 mmol) of triethylamine and then 38.8 g (66 mmol) of 10-(3-amino-2 hydroxypropyl)- 1,4,7-tris-(tert-butoxycarbonylmethyl)- 1,4,7,1 0-tetraazacyclododecane are added to 12.86 g (20 mmol) of 1,3,5-triiodotrimesic acid tris chloride (DE 3001292, Schering AG, priority: 1/11/1980),. dissolved in 400 ml of tetrahydrofuran, and it is stirred for 6 hours at room temperature. Insoluble components are filtered out, it is evaporated to the dry state, and chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20: 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 32.7 g (71% of theory) of a colorless solid Elementary analysis: Cld.: C 50.19 H 7.37 N 9.15 116.57 Fnd.: C 50.33 H 7.40 N 9.11 116.43 f) 1,3,5-Triiodotrimesic acid-NN,N-tris-(2-hydroxypropane-1,3-diyl-{10-[1,4,7 tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})amide 34.5 g (15 mmol) of 1,3,5-triiodotrimesic acid-N,NN-tris-(2-hydroxypropane 1,3-diyl-{10-[1,4,7-tris-(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclo dodecanyl]})amide is dissolved in 100 ml of dichloromethane, mixed at 0*C with 100 ml 48 of trifluoroacetic acid and stirred for 3 hours at 0 0 C. The batch is poured into 500 ml of diethyl ether; the solid that accumulates is filtered off, rewashed three times with 100 ml each of diethyl ether and dried in a vacuum. Yield: 25.3 g (94% of theory) of a colorless solid Elementary analysis: Cid.: C 40.21 H 5.40 N 11.72 121.24 Fnd.: C40.44 H5.49 N11.67 121.11 g) 1,3,5-Triiodotrimesic acid-NN,N-tris-(2-hydroxypropane-1,3-diyl-{10-[1,4,7 tris-(carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl]}, Gd complex)amide 21.5 g (12 mmol) of 1,3,5-triiodotrimesic acid-N,N,N-tris-(2-hydroxypropane 1,3-diyl-{10-[1,4,7--tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})amide is dissolved in 250 ml-of water and acidified by adding 5 ml of acetic acid. 13 g (36.2 mmol) of gadolinium oxide is added and refluxed for 3 hours. After complexing is completed, the pH is set at 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). .The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze-dried. Yield: 19.4 g (68% of theory) of a colorless solid Water content (Karl-Fischer): 5.3% 49 Elementary analysis (relative to anhydrous substance): Cld.: C 31.96 H 3.89 N 9.32 I 16.88 Gd 20.92 Fnd.: C 32.11 H 3.94 N 9.28 116.77 Gd 20.79 Example 6 a) 1-Benzyl-1-methyl(oxiranylmethyl)amine 60.6 g (0.5 mol) of benzylmethylamine and 55.5 g (0.6 mol) of epichlorohydrin are dissolved in 500 ml of methanol and heated for 6 hours to 80'C. The solution is evaporated to the dry state and mixed with 500 ml of tert-butanol. A solution of 36.4 g (0.65 mol) of potassium hydroxide in 50 ml of water is now added while being stirred, and it is heated for 2 hours to 80*C. After cooling to room temperature, potassium chloride that has formed is filtered out, the filtrate is evaporated to the dry state and chromatographed on silica gel (mobile solvent: hexane/ethyl acetate 10 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 85 g (96% of theory) of a colorless oil Elementary analysis: Cld.: C 74.54 H 8.53 N 7.90 Fnd.: C 74.68 H 8.55 N 7.82 b) [1-(3-Benzylmethylamino-2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane] pentahydrochloride 100 ml (752.77 mmol) of NN-diniethylformamide dimethyl acetal is added to 100 g (580.48 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 700 ml of toluene, and it is heated for 2 hours to 120*C under nitrogen. In this case, a methanol/toluene 50 azeotrope is continuously distilled off. Then, the reaction mixture is concentrated by evaporation at 70'C in a vacuum, 110 g (620 mmol) of 1-benzyl-1 methyl(oxiranylmethyl)amine is added, and it is heated under nitrogen for 24 hours to 110 C. After cooling to room temperature, it is mixed with 500 ml of water and extracted twice with 200 ml each of ethyl acetate. The aqueous phase is mixed with 250 ml of concentrated HCl and then heated for 12 hours to 80*C. It is evaporated to the dry state, mixed with 200 ml of ethanol and 200 ml of methanol and again evaporated to the dry state. The residue is dissolved in 600 ml of ethanol while being heated, and then it is slowly cooled to 0 0 C, whereby a white solid crystallizes out. The-solid is filtered off, washed with ethanol and then dried at 50*C in a vacuum. Yield: 235 g (76% of theory) of a colorless solid Elementary analysis: Cld.: C 42.91 H 7.58 N 13.17 Cl 33.33 Fnd.: C-43.34 H 7.60 N 13.29 Cl 32.78 c) 10-(3-Benzylmethylamino-2-hydroxypropyl)-1,4,7-tris-(tert butoxycarbonylmethyl)-1,4,7, 1 0-tetraazacyclododecane 32% NaOH solution is added to 212.7 g (400 mmol) of [1-(3 benzylmethylamino-2-hydroxypropyl) 1,4,7,1 0-tetraazacyclododecane] pentahydrochloride, dissolved in 500 ml of water and 500 ml of dichloromethane, while being stirred vigorously until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 250 ml each of dichloromethane, the combined organic phases are.dried on magnesium sulfate and evaporated to the dry state. The residue is dissolved in 1200 ml of acetonitrile and mixed with 176.2 g (1.275 mol) 51 of potassium carbonate. Then, 248.7 g (1.275 mol) of bromoacetic acid-tert-butyl ester is added while being stirred vigorously, and it is heated for 3 hours to 60'C. Insoluble components are filtered out, it is evaporated to the dry state, and chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 219 g (79% of theory) of a colorless solid Elementary analysis: Cld.: C 64.23 H 9.47 N 10.12 Fnd.: C-64.38 H 9.50 N 10.07 d) 10-(3-Methylamino-2-hydroxypropyl)-1,4,7-tris-(tert-butoxycarbonylmethyl) 1,4,7,1 0-tetraazacyclododecane 69.2 g (100 mmol) of 10-(3 -benzylmethylamino-2-hydroxypropyl) 1,4,7-tris (tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane is dissolved in 500 ml of methanol, mixed with 40 ml of water, and 10 g of palladium catalyst (20% Pd/C) is added. It is hydrogenated for 8 hours at 50*C under normal pressure. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum. Yield: 60 g (quantitative) of a colorless powder Elementary analysis: Cld.: C 59.67 H 9.88 N 11.64 Fnd.: C 59.89 H 9.81 N 11.52 52 e) 1,3,5-Triiodotrimesic acid-N,N,N-tris-(2-hydroxypropane-1,3-diyl-{ 10-[1,4,7 tris-(tert-butoxycarbonylmethyl)- 1,4,7,1 0-tetraazacyclododecanyl] })methylamide 12.2 g (120 mmol) of triethylamine and then 39.7 g (66 mmol) of 10-(3 methylamino-2-hydroxypropyl)-1,4,7-tris-(tert-butoxycarbonylmethyl)-1,4,7,10 tetraazacyclododecane are added to 12.86 g (20 mmol) of 1,3,5-triiodotrimesic acid tris chloride (DE 3001292, Schering AG, priority: 1/11/1980), dissolved in 400 ml of tetrahydrofuran, and it is stirred for 18 hours at room temperature. Insoluble components are filtered out, it is evaporated to the dry state and chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 31.4 g (67% of theory) of a colorless solid Elementary analysis: Cld.: C 50.83 H 7.50 N 8.98 116.41 Fnd.: C 50.99 H 7.57 N 8.90 116.22 1,3,5-Triiodotrimesic acid-N,N,N-tris-(2-hydroxypropane-1,3-diyl-{ 10-[1,4,7 tris-(carboxymethyl)- 1,4,7,1 0-tetraazacyclododecanyl] })methylamide 35.1 g (15 mmol) of 1,3,5-triiodotrimesic acid-N,N,N-tris-(2-hydroxypropane 1,3 -diyl- {10-[1,4,7-tris-(tert-butoxycarbonylmethyl)- 1,4,7,1 0-tetraazacyclododecanyl] }) methylamide is dissolved in 100 ml of dichloromethane, mixed at 0*C with 100 ml of trifluoroacetic acid and stirred for 3 hours at 0*C. The batch is poured into 500 ml of diethyl ether; the solid that accumulates is filtered off, it is rewashed three times with 100 ml each of diethyl ether and dried in a vacuum. Yield: 26.4 g (96% of theory) of a colorless solid 53 Elementary analysis: Cld.: C 40.25 H 5.60 N 11.45 120.75 Fnd.: C 40.17 H 5.69 N 11.51 120.58 g) 1,3,5-Triiodotrimesic acid-NN,N-tris-(2-hydroxypropane-1,3 -diyl-{I 0-[1,4,7 tris-(carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl] Gd complex) methylamide 22 g (12 mmol) of 1,3,5-triiodotrimesic acid-NN,N-tris-(2-hydroxypropane-1,3 diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})methylamide is dissolved in 250 ml of water and acidified by adding 5 ml of acetic acid. 13 g (36.2 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours. After complexing is completed, the pH is set at 7.4 with ammonia and chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze-dried. -Yield: 18.2 g (62% of theory) of a colorless solid Water content (Karl-Fischer): 6.1% Elementary analysis (relative to the anhydrous substance): Cld.: C 32.94 H 4.08 N 9.15 1 16.57 Gd 20.54 Fnd.: C33.21 H4.13 N9.10 116.43 Gd20.22 54 Example 7 a) 1,3,5-Triiodo-2,4,6-tris-(oxiranylmethoxymethyl)benzene 55 ml of a 32% NaOH solution is added in drops at room temperature to a mixture that consists of 11.0 g (20.1 mmol) of 1,3,5-triiodo-2,4,6 trishydroxymethylbenzene, 55.5 g (0.6 mol) of epichlorohydrin and 1.1 g (3.2 mmol) of tetrabutylammonium hydrogen sulfate within 1 hour, and then it is stirred for 12 hours. It is mixed with 150 ml of water and extracted twice with 200 ml each of toluene. The combined organic phases are dried on sodium sulfate, the solvent is evaporated to the dry state and chromatographed on silica gel (mobile solvent: hexane/ethyl acetate 10: 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 10.5 g (73% of theory) of a colorless solid Elementary analysis: Cld.: C 30.28 H 2.96 153.32 Fnd.: C 30.44 H 2.99 I 53.21 b) 1,3,5-Triiodo- {2,4,6-tris[2-hydroxy-3-(1,4,7,1 0-tetraazacyclododecan- 1 yl)propyloxy-methyl]} benzene 10 ml (75.28 mmol) of N,N-dimethylformamide dimethyl acetal is added to 10 g (58.05 mmol) of 1,4,7,10-tetraazacyclododecane, dissolved in 100 ml of toluene, and it is heated for 2 hours to 120*C under nitrogen. In this case, a methanol/toluene azeotrope is distilled off.continuously. Then, the reaction mixture is concentrated by evaporation at 70'C in a vacuum, 13.6 g (19.1 mmol) of 1,3,5-triiodo-2,4,6-tris (oxiranylmethoxymethyl)benzene is added, and it is heated under nitrogen for 24 hours 55 to 110 C. After cooling to room temperature, it is mixed with 100 ml of 2N HCI and then heated for 12 hours to 80*C. It is evaporated to the dry state, mixed with 50 ml of ethanol and 50 ml of methanol and evaporated to the dry state again. The residue is dissolved in 100 ml of ethanol while being heated, and then slowly cooled to 0 0 C, whereby a white solid crystallizes out. The solid is filtered off, washed with ethanol and then dried at 50*C in a vacuum. The solid is dissolved in 100 ml of water and 100 ml of dichloromethane, and 32% NaOH solution is added while being stirred vigorously until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 100 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 19.0 g (81% of theory) of a colorless solid Elementary analysis: Cld.: C 40.98 H 6.63 N 13.66 130.93 Fnd.: C 41.32 H 6.71 N 13.54 130.77 c) 1,3,5-Triiodo- {2,4,6-tris[2-hydroxy-3-(1,4,7-triscarboxymethyl-1,4,7,10 tetraazacyclododecan-1 -yl)propyloxymethyl] }benzene 16.6 g (13.5 mmol) of 1,3,5-triiodo-{2,4,6-tris[2-hydroxy-3-(1,4,7,10 tetraazacyclododecan-1-yl)propyloxy-methyl]}benzene is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60*C with 32% NaOH. It is heated for 10 hours to 70*C, whereby the pH of the reaction mixture is continuously readjusted to 9.5. After cooling to room temperature, a pH of 1 is set with concentrated HCl, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are 56 filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H*-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 14.4 g (61% of theory) of a colorless solid Elementary analysis: Cld.: C41.11 H5.69 N 9.59 121.71 Fnd.: C 41.34 H 5.56 N 9.62 I 21.45 d) 1,3,5-Triiodo-{2,4,6-tris[2-hydroxy-3-(1,4,7-triscarboxylatomethyl-1,4,7,10 tetraazacyclododecan- 1 -yl)propyloxymethyl] Gd complex} benzene 12.1 g (6.9 mmol) of 1,3,5-triiodo-{2,4,6-tris[2-hydroxy-3-(1,4,7 triscarboxymethyl- 1,4,7,1 0-tetraazacyclododecan- 1 -yl)propyloxymethyl]} benzene is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 7.0 g (43% of theory) of a colorless solid 57 Water content (Karl-Fischer): 5.4% Elementary analysis (relative to the anhydrous substance): Cld.: C 32.52 H 4.09 N 7.59 117.18 Gd 21.29 Fnd.: C 32.88 H 4.19 N 7.62 117.00 Gd 20.99 Example 8 a) - 10-[4-Aza-6-(benzyloxycarbonylamino)-5-oxo-2-hydroxyhexyl]- 1,4,7-tris-(tert butoxycarbonylmethyl)- 1,4,7,1 0-tetraazacyclododecane 21.97 g (105 mmol) of Z-glycine is dissolved in 400 ml of DMF, mixed with 12.1 g (105 mmol) of N-hydroxysuccinimide and 21.7 g (105 mmol) of dicyclohexylcarbodiimide while being cooled with ice and preactivated for 1 hour in ice. Then, 58.8 g (100 mmol) of 10-(3-amino-2-hydroxypropyl)-1,4,7-tris-(tert butoxycarbonylmethyl)-.,4,7,10-tetraazacyclododecane and 15.4 ml (120 mmol) of triethylamine are added and stirred overnight at room temperature. Insoluble components are filtered out and evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500. ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20: 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 63.2 g (81% of theory) of a colorless solid Elementary analysis: Cld.: C 60.13 H 8.54 N 10.79 Fnd.: C 60.32 H 8.561 N 10.59 58 b) 10-(4-Aza-6-amino-5-oxo-2-hydroxyhexyl)- 1,4,7-tris-(tert butoxycarbonylmethyl)- 1,4,7,1 0-tetraazacyclododecane 60 g (77 mmol) of 10-[4-aza-6-(benzyloxycarbonylamino)-5-oxo-2 hydroxyhexyl]-1,4,7-tris-(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane is dissolved in 500 ml of niethanol, mixed with 40 ml of water, and 10 g of palladium catalyst (10% Pd/C) is added. It is hydrogenated for 8 hours at 50'C under normal pressure. Catalyst is filtered out, and the filtrate is evaporated to the dry state. Yield: 48.8 g (98% of theory) of a colorless solid Elementary analysis: Cld.: C 57.74 H 9.38 N 13.03 Fnd.: C 57.68 H 9.44 N 13.11 c) 1,3,5-Triiodotrimesic acid-NN,N-tris-(3-aza-2-oxo-5-hydroxyhexane-1,6-diyl { 10-[1,4,7-tris-(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecanyl]}) amide 12.2 g (120 mmol) of triethylamine and then 42.6 g (66 mmol) of 10-(4-aza-6 amino-5-oxo-2-hydroxyhexyl)- 1,4,7-tris-(tert-butoxycarbonylmethyl)- 1,4,7,10 tetraazacyclododecane are added to 12.86 g (20 mmol) of 1,3,5-triiodotrimesic acid tris chloride (DE 3001292, Schering AG, priority: 1/11/1980), dissolved in 400 ml of tetrahydrofuran, and it is stirred for 6 hours at room temperature. Insoluble components are filtered out, evaporated to the dry state and chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 36.5 g (74% of theory) of a colorless solid 59 Elementary analysis: Cld.: C 49.63 H 7.23 N 10.21 115.42 Fnd.: C 49.97 H 7.31 N 10.12 115.26 d) 1,3,5-Triiodotrimesic acid-N,N,N-tris-(3-aza-2-oxo-5-hydroxyhexane-1,6-diyl {10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})amide 34.6 g (14 mmol) of 1,3,5-triiodotrimesic acid-N,N,N-tris-(3-aza-2-oxo-5 hydroxyhexane-1,6-diyl-{10-[1,4,7-tris-(tert-butoxycarbonylmethyl)-1,4,7,10 tetraazacyclododecanyl]})amide is dissolved in 100 ml of dichloromethane, mixed at 0 0 C with 100 ml of trifluoroacetic acid and stirred for 3 hours at 0 0 C. The batch is poured into 500 ml of diethyl ether; the solid that accumulates is filtered off, rewashed three times with 100 ml each of diethyl ether and dried in a vacuum. Yield: 26.0 g (95% of theory) of a colorless solid Elementary analysis: Cld.: C 40.38 H 5.39 N 12.84 119.39 Fnd.: C 40.56 H 5.45 N 12.78 119.17 e) 1,3,5-Triiodotrimesic acid-NNN-tris-(3 -aza-2-oxo-5-hydroxyhexane-1,6-diyl . 10-[1,4,7-tris-(carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl]}, Gd complex)amide 23.6 g (12 mmol) of 1,3,5-triiodotrimesic acid-N,NN-tris-(3-aza-2-oxo-5 hydroxyhexane-1,6-diyl-{ 10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclo dodecanyl]})amide is dissolved in 250 ml of water and acidified by adding 5 ml of acetic acid. 13 g (36.2 mmol) of gadolinium oxide is added, and it is refluxed for 3 hours.
60 After complexing is completed, the pH is set at 7.4 again with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 20/20/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze-dried. Yield: 20.8 g (67% of theory) of a colorless solid Water content (Karl-Fischer): 6.4% Elementary analysis (relative to the anhydrous substance): Cld.: C 32.68 H 3.99 N 10.39 115.69 Gd 19.45 Fnd.: C 32.99 H 4.07 N 10.35 115.53 Gd 19.22 Example 9 a) 1,3,5-Triiodo-2,4,6-tris-(toluenesulfonyloxy)methylbenzene 76.3 g (400-mmol).of toluenesulfonic acid chloride is added in drops to a mixture that consists of 50.0 g (91.4 mmol) of 1,3,5-triiodo-2,4,6-tris-hydroxymethylbenzene and 3 g (8.7 mmol) of tetrabutylammonium hydrogen sulfate in 200 ml of 32% NaOH solution and 300 ml of toluene at room temperature, and then it is stirred for 12 hours. It is mixed with 300 ml of water and extracted twice with 200 ml each of toluene. The combined organic phases are dried on sodium sulfate, the solvent is evaporated to the dry state and chromatographed on silica gel (mobile solvent: hexane/ethyl acetate 10 : 1). The fractions that contain the product are combined and concentrated by evaporation.
61 Yield: 47.2 g (51% of theory) of a colorless solid Elementary analysis: Cld.: C 35.73 H 2.70 137.75 Fnd.: C 36.03 H 2.77 I 37.56 b) 1,4,7-Tris-(benzyloxycarbonyl)- 1 0-(carbamidomethyl)- 1,4,7,10 tetrazacyclododecane 17.8 g (130.5 mmol) of isobutyl chloroformate-is added in drops at -20*C to a solution of 75 g (118.7 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-10-(carboxymethyl) 1,4,7,10-tetrazacyclododecane.and 16.9 g (130.5 mmol) of diisopropylethylamine in 500 ml of THF. Then, it is stirred for 1 hour at -20*C and mixed carefully with 20 ml of 25% aqueous ammonia solution. It is stirred for 2 more hours at 0*C, then the solvent is distilled off in a vacuum and the residue is chromatographed on silica gel (mobile solvent: ethyl acetate/hexane 10 :1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 60.7 g (81% of theory) of a colorless solid Elementary analysis: Cld.: C 64.64 H 6.54 N 11.09 Fnd.: C 64.81 H 6.549 N 11.00 c) 1,3,5-Triiodo-2,4,6-tris-(2-aza-3-oxobutane-1,4-diyl-{ 10-[1,4,7-tris (benzyloxycarbonyl)- 1,4,7,1 0-tetraazacyclododecanyl] })benzene 44.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-10-(carbamidomethyl) 1,4,7,10-tetrazacyclododecane is dissolved in 500 ml of THF and mixed at 0*C under 62 argon with 1.71 g (71 mmol) of sodium hydride and stirred for 1 hour at room temperature. Then, a solution of 20.2 g (20 mmol) of 1,3,5-triiodo-2,4,6-tris (toluenesulfonyloxy)methylbenzene in 150 ml of THF is added in drops and refluxed for 20 hours. After cooling, insoluble components are filtered out and evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: .dichloromethane/methanol 20: 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 29.4 g (62% of theory) of a colorless solid Elementary analysis: Cld.: C 55.85 H 5.32 N 8.80 115.95 Fnd.: C 56.07 H 5.39 N 8.67 115.76 d) 1,3,5-Triiodo-2,4,6-tris-{2-aza-3-oxobutane-1,4-diyl-[10-(1,4,7,10tetraazacyclododecanyl)] }benzene 20 g (8.4 mmol) of 1,3,5-triiodo-2,4,6-tris-(2-aza-3-oxobutane-1,4-diyl-{10 [1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})benzene is carefully mixed at 0-5 0 C [with] 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 ml of diethyl ether; the solid that accumulates in this case is suctioned off, and it is rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase, is separated, the aqueous phase is extracted three 63 times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 9.1 g (91% of theory) of a colorless solid Elementary analysis: Cld.: C 39.70 H 6.15 N 17.81 132.27 Fnd.: C 39.91 H 6.22 N 17.75 I 32.09 e) .1,3,5-Triiodo-2,4,6-tris-(2-aza-3-oxobutane-1,4-diyl-{ 10-[1,4,7-tris (carboxymethyl)- 1,4,7,1 0-tetraazacyclododecanyl] })benzene 17.7 g (15 mmol) of 1,3,5-triiodo-2,4,6-tris-{2-aza-3-oxobutane-1,4-diyl-[10 (1,4,7,10-tetraazacyclododecanyl)]}benzene is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60'C with 32% NaOH. It is heated for 10 hours to 70'C, whereby the pH of the reaction mixture is readjusted continuously to 9.5. After cooling to room temperature, the pH is set at 1 with concentrated HCl, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H*-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 13.8 g (54% of theory) of a colorless solid 64 Elementary analysis: Cid.: C 40.22 H 5.33 N 12.34 I 22.37 Fnd.: C 40.43 H 5.37 N 12.25 I 22.19 f) 1,3,5-Triiodo-2,4,6-tris-(2-aza-3-oxobutane-1,4-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl] }, Gd complex)benzene 11.7 g (6.9 mmol) of 1,3,5-triiodo-2,4,6-tris-(2-aza-3-oxobutane-1,4-diyl-{ 10 [1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})benzene is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 1.0/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 8.4 g (53% of theory) of a colorless solid Water content (Karl-Fischer): 6.1% Elementary analysis (relative to the anhydrous substance): Cld.: C 31.63 H 3.77 N 9.71 117.59 Gd 21.79 Fnd.: C 31.77 H 3.72 N 9.76 117.45 Gd 21.63 65 g) 1,3,5-Triiodo-2,4,6-tris-(2-aza-3-oxobutane- 1,4-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl]}, Dy complex)benzene 11.7 g (6.9 mmol) of 1,3,5-triiodo-{2,4,6-tris-[2-(4,7,10-triscarboxymethyl 1,4,7,10-tetraazacyclododecan-1-ylacetylamino)methyl]}benzene is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.88 g (10.4 mmol) of dysprosium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with. 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 7.5 g (47% of theory) of a colorless solid Water content (Karl-Fischer): 5.9% Elementary analysis (relative to the anhydrous substance): CId.: C 31.40 H 3.74 N 9.64 117.46 Dy 22.36 Fnd.: C 31.65 H 3.79 N 9.67 117.25 Dy 22.11 h) 1,3,5-Triiodo-2,4,6-tris-(2-aza-3-oxobutane-1,4-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl] },Y complex)benzene 11.7 g (6.9 mmol) of 1,3,5-triiodo-{2,4,6-tris-[2-(4,7,10-triscarboxymethyl 1,4,7,1 0-tetraazacyclododecan- 1 -ylacetylamiiio)methyl] }benzene is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.72 g (10.4 mmol) of yttrium carbonate is added, and it is refluxed for 6 hours. After complexing is completed, the 66 pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/1.0/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze-dried. Yield: 8.7 g (61% of theory) of a colorless solid Water content (Karl-Fischer): 5.4% Elementary analysis (relative to the anhydrous substance): Cld.: C 34.93 H 4.17 N 10.72 119.43 Y 13.61 Fnd.: C 35.12 H 4.11 N 10.79 119.34 Y 13.52 Example 10 a) 1,4,7-Tris-(benzyloxycarb6nyI)-1 0-(1 -carbamidoethyl)- 1,4,7,10 tetrazacyclododecane 17.8 g (130.5 mmol) of isobutyl chloroformate is added in drops to a solution of 76.8 g (118.7 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-1 0-(1 -carboxyethyl)- 1,4,7,10 tetrazacyclododecane and 16.9 g (130.5 mmol) of diisopropylethylamine in 500 ml of THF at -20 0 C. Then, it is stirred for 1 hour at -20*C and carefully mixed with 20 ml of 25% aqueous ammonia solution. It is stirred for 2 more hours at 0 0 C, then the solvent is distilled off in a vacuum, and the residue is chromatographed on silica gel (mobile solvent: ethyl acetate/hexane 10 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 59.8 g (78% of theory) of a colorless solid 67 Elementary analysis: Cid.: C65.10 H6.71 N10.85 Fnd.: C 65.34 H 6.86 N 10.67 b) 1,3,5-Triiodo-2,4,6-tris-(2-aza-4-methyl-3-oxobutane-1,4-diyl-{ 10-[1,4,7-tris (benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})benzene .45.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-1 0-(l -carbamidoethyl) 1,4,7,10-tetrazacyclododecane is dissolved in 500 ml of THF and mixed at 0*C under argon with 1.71 g (71 mmol) of sodium hydride and stirred for 1 hour at room temperature. Then, a solution of 20.2 g (20 mmol) of 1,3 ,5-triiodo-2,4,6-tris (toluenesulfonyloxy)methylbenzene in 150 ml of THF is added in drops and stirred for 20 hours under reflux. After cooling, insoluble components are filtered out and evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 27.7 g (57% of theory) of a colorless solid Elementary analysis: Cid.: C 56.37 H 5.48 N 8.65 115.67 Fnd.: C 56.56 H 5.39 N 8.73 115.46 68 c) 1,3,5-Triiodo-2,4,6-tris- {2-aza-4-methyl-3-oxobutane- 1,4-diyl-[ 10-(1,4,7,10 tetraazacyclododecanyl)]}benzene 25 g (10.3 mmol) of 1,3,5-triiodo-2,4,6-tris-(2-aza-4-methyl-3 -oxobutane- 1,4 diyl-{ 10-[1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})benzene is carefully mixed at 0-5*C with 150 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 ml of diethyl ether; the solid that accumulates in this case is suctioned off, and it is rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three, times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 11.4 g (90% of theory) of a colorless solid Elementary analysis: Cld.: C 41.29 H 6.43 N 17.19 131.16 Fnd.: C 41.44 H 6.49 N 17.07 131.00 d) 1,3,5-Triiodo-2,4,6-tris-(2-aza-4-methyl-3-oxobutane-1,4-diyl-{ 10-[1,4,7-tris.
(carboxymethyl)- 1,4,7,1 0-tetraazacyclododecanyl] })benzene 18.3 g (15 mmol) of 1,3,5-triiodo-2,4,6-tris-{2-aza-4-methyl-3-oxobutane-1,4 diyl-[10-(1,4,7,10-tetraazacyclododecanyl)]}benzene is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60*C with 32% NaOH. It is heated for 10 hours to 70'C, whereby the pH of the reaction mixture is continuously readjusted to 9.5. After cooling to room temperature, a pH of 1 is set with 69 concentrated HCl, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H*-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 15.5 g (59% of theory) of a colorless solid Elementary analysis: Cld.: C 41.32 H 5.55 N 12.05 121.83 Fnd.: C 41.56 H 5.62 N 12.01 121.73 e) 1,3,5-Triiodo-2,4,6-tris-(2-aza-4-methyl-3-oxobutane-1,4-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)-l'4,7,10-tetraazacyclododecanyl]}, Gd complex)benzene 12.0 g (6.9 mmol) of 1,3,5-triiodo-2,4,6-tris-(2-aza-4-methyl-3-oxobutane-1,4 diyl-{ 10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl] })benzene is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, a pH of 7.4 is set with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then it is absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, 70 mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze dried. Yield: 7.6 g (47% of theory) of a colorless solid Water content (Karl-Fischer): 5.2% Elementary analysis (relative to the anhydrous substance): Cid.: C 32.66 H 3.97 N 9.52 117.25 Gd 21.38 Fnd.: C 32.78 H 3.99 N 9.45 117.21 Gd 21.19 Example 11 a) 10-[4-Carbamido-1-methyl-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane 1,4,7-triacetic acid-tert-butyl ester 17.8 g (130.5 mmol) of isobutyl chloroformate is added in drops at -20*C to a solution of 76.5 g (118.7 mmol) of 10-[4-carboxy-l-methyl-2-oxo-3-azabutyl]1,4,7,10 tetraazacyclododecane-1,4,7-triacetic acid-tert-butyl ester (DE 19549286 Al, Schering AG, (Example 2d)) and 16.9 g (130.5 mmol) of diisopropylethylamine in 500 ml of THF. Then, it is stirred for 1 hour at -20*C and carefully mixed with 20 ml of 25% aqueous ammonia solution. It is stirred for 2 more hours at 0*C, then, the solvent is distilled off in a vacuum, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 61.1 g (80% of theory) of a colorless solid Elementary analysis: Cld.: C 57.92 H 9.09 N 13.07 Fnd.: C 58.11 H 9.12 N 12.99 71 6-dioxo- 7 -methyIheptane- ,7-diyl- 10 1,3,5-Triiodo-2,4,6-tris-(2,5-diaza-3,6doO--eh b) 471-eraacyclo {1, 4
,
7 -tris-(tert-butyloxycarbonylmeth)-1, etraaZ dodecanyl)})benzene -2 oxo-3-azabutyl)-1,4,7,10 f 10[4-crbamdo-1I-methy 44.6 g (70.6 mmol) of diss 4 vcarbae0lden50lloxH 47-triacetic acid-tert-butyl ester is dissolved in 500 Ml of TF tetraazacyclododecane- 1,4,go 1.71g (71 mmoD of sodium hydride, and it is stirred and -mixed at 0*C under argon W ouino 02g(0mo)of 1,3,5-triiodo for1 hurat room temperatre. Then, a solution of 20.2 g (20 mmOl) ofan5~fid for I hour in 150 ml of THF is added in drops and 2,4,6-tris -(une elufor yoym e oling, insoluble components are filtered out -stirred under refu for 20ke hours. 500 MI Of ethyl acetate and. and evaporated to the dry state. The residue is taken up in drid of sodium 500 ml each of water. The organic phase is extracted twice with d thMrsiu is chromatographed on sulfate, the solvent is evaporated to the dry state, and the residue ato h on lvent dichloromethane/methanol 20 The fractions that contain silica gel (mobile solet the product are combined and concentrated by evaporation. Yield: 15.1 g (31% of theory) of a colorless solid Elementary analysis: CId.: C50.6 2 147.37 N10.
42 115.73 Fnd.: C50.79 H7.41 N10.
4 4 115.64 S246 s( 2 5 diaza 3 6-dioxo-7-ethylheptane-,7-diyl-(10 c) 13 5-Triodo246trs(,-daa3 c)1''acyclododecanYl)})benzene [1 .4,7 -tris-(carboxymnethy 0,471-era . 18.2 g (7.5 mmOl) of 1,3 ,5-triiodo-2,4,6-tris-( 2 ,5-diaza-3,6-dioxo-7. methylheptanel ,7-diyl-{10-[ 1
,
4
,
7 -tris-(tert-butyloxycarbony lmethyl- 10 meth-dissolved in 75 ml of dichloromethane, mixed at tetraazacyclododecany l)})benzene is dsovdi 72 0*C with 75 ml of trifluoroacetic acid and stirred for 3 hours at 0*C. The batch is poured into 500 ml of diethyl ether; the solid that accumulates is filtered off, rewashed three times with 100 ml each of diethyl ether and dried in a vacuum. Yield: 14.1 g (98% of theory) of a colorless solid Elementary analysis: Cld.: C 41.39 H 5.53 N 13.16 119.88 Fnd.: C 41.51 H 5.57 N 13.11 119.67 d). 1,3,5-Triiodo-2,4,6-tris-(2,5-diaza-3,6-dioxo-7-methylheptane-1,7-diyl-{10 [1,4,7-tris-(carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl]}, Gd complex)benzene 13.2 g (6.9 mmol) of 1,3,5-triiodo-2,4,6-tris-(2,5-diaza-3,6-dioxo-7 methylheptane-1,7-diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclo dodecanyl]})benzene is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g.of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then it is absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 10.2 g (58% of theory) of a colorless solid Water content (Karl-Fischer): 6.2% 73 Elementary analysis (relative to the anhydrous substance): Cld.: C 33.34 H 4.07 N 10.60 116.01 Gd 19.84 Fnd.: C 33.52 H 4.12 N 10.63 115.89 Gd 19.72 Example 12 a) 10-(4-Carbamido-2-oxo-3-azabutyl)-1,4,7,10-tetraazacyclododecane-1,4,7 triacetic acid-tert-butyl ester 17.8 g (130.5.mmol) of isobutyl chloroformate is added in drops at-20*C to a solution of 74.8 g (118.7 mmol) of 10-(4-carboxy-2-oxo-3-azabutyl)-1,4,7,10-tetraaza cyclododecane-1,4,7-triacetic acid-tert-butyl ester (DE 19549286 Al, Schering AG, (Example li)) and 16.9 g (130.5 mmol) of diisopropylethylamine in 500 ml of THF. Then, it is stirred for 1 hour at -20'C and carefully mixed with 20 ml of 25% aqueous ammonia solution. It is stirred for 2 more hours at 0*C, and then the solvent is distilled off in a vacuum, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 55.9 g (75% of theory) of a colorless solid Elementary analysis: Cld..: C 57.30 H 8.98 N 13.36 Fnd.: C 57.45 H 8.99 N 13.31 74 b) 1,3,5-Triiodo-2,4,6-tris-(2,5-diaza-3,6-dioxoheptane-1,7-diyl-{ 10-[1,4,7-tris (tert-butyloxycarbonylmethyl)- 1,4,7,1 0-tetraazacyclododecanyl] })benzene 44.4 g (70.6 mmol) of 10-(4-carbamido-2-oxo-3 -azabutyl)- 1,4,7,1 0-tetraaza cyclododecane-1,4,7-triacetic acid-tert-butyl ester is dissolved in 500 ml of THF and mixed at 0*C under argon with 1.71 g (71 mmol) of sodium hydride, and it is stirred for 1 hour at room temperature. Then, a solution of 20.2 g (20 mmol) of 1,3,5-triiodo-2,4,6 tris-(toluenesulfonyloxy)methylbenzene in 150 ml of THF is added in drops and stirred under reflux for 20 hours. After cooling, insoluble components are filtered out, and it is evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 16.2 g (34% of theory) of a colorless solid Elementary analysis: Cld.: C 50.00 H 7.25 N 10.60 116.01 Fnd.: C 50.17 H 7.28 N 10.55 115.89 c) 1,3,5-Triiodo-2,4,6-tris-(2,5-diaza-3,6-dioxoheptane-1,7-diyl-{ 10-[1,4,7-tris (carboxymethyl)-i1,4,7,1 0-tetraazacyclododecanyl] })benzene 17.9 g (7.5 mmol) of 1,3,5-triiodo-2,4,6-tris-(2,5-diaza-3,6-dioxoheptane-1,7 diyl-{l 0-[1,4,7-tris-(tert-butyloxycarbonylmethyl)-1,4,7,10-tetraazacyclo dodecanyl]})benzene is dissolved in 75 ml of dichloromethane, mixed at 0 0 C with 75 ml of trifluoroacetic acid and stirred for 3 hours at 0*C. The batch is poured into 500 ml of 75 diethyl ether; the solid that accumulates is filtered off, rewashed three times with 100 ml each of diethyl ether and dried in a vacuum. Yield: 13.5 g (96% of theory) of a colorless solid Elementary analysis: Cld.: C 40.39 H 5.33 N 13.46 I 20.32 Fnd.: C 40.21 H 5.27 N 13.57 I 20.22 d) 1,3,5-Triiodo-2,4,6-tris-(2,5-diaza-3,6-dioxoheptane-1,7-diyl-{10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl] }, Gd complex)benzene 12.9 g (6.9 mmol) of 1,3,5-triiodo-2,4,6-tris-(2,5-diaza-3,6-dioxoheptane-1,7 diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyciododecanyl]})benzene is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then it is absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze dried. Yield: 10.6 g (61% of theory) of a colorless solid Water content (Karl-Fischer): 6.5% 76 Elementary analysis (relative to the anhydrous substance): Cld.: C 32.39 H 3.88 N 10.79 I 16.30 Gd 20.19 Fnd.: C32.51 H3.91 N 10.75 116.16 Gd20.01 Example 13 a) 2,4,6-Triiodo- 1,3,5-tris-(2-tert-butoxycarbonylaminoethoxymethyl)benzene 142 g (450 mmol) of toluenesulfonic acid-2-tert-butoxycarbonylaminoethyl ester (Canne et al., Tetrahedron Letters, 38, 1997, 3361), dissolved in 250 ml of toluene, is added in drops to a mixture that consists of 50.0 g (91.4 mmol) of 1,3,5-triiodo-2,4,6 trishydroxymethylbenzene, and 3 g (8.7 mmol) of tetrabutylammonium hydrogen sulfate in 200 ml of 32% NaOH solution and 300 ml of toluene at room temperature, and then it is stirred for 12 hours. It is mixed with water and extracted twice with 300 ml each of toluene. The combined organic phases are dried on sodium sulfate, the solvent is evaporated to the dry state and chromatographed on silica gel (mobile solvent: hexane/ethyl acetate 10: 1).. The fractions that contain the product are combined and concentrated by evaporation. Yield: 28.6 g (32% of theory) of a colorless solid Elementary analysis: Cld.: C 36.94 H 4.96 N 4.31 137.75 Fnd.: C 36.98 H 4.90 N 4.27 137.64 b) 2,4,6-Triiodo- 1,3,5-tris-(aminoethoxymethyl)benzene 24.4 g (25 rnmol) of 2,4,6-triiodo-1,3,5-tris-(2-tert-butoxycarbonylaminoethoxy methyl)benzene is dissolved in 100 ml of dichloromethane, mixed at 0*C with 100 ml of 77 trifluoroacetic acid and stirred for 3 hours at 0 0 C. The batch is poured into 500 ml of diethyl ether; the solid that accumulates in this case is suctioned off and rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 14.7 g (87% of theory) of a colorless solid Elementary analysis: Cld.: C 26.69 H 3.58 N 6.22 I 56.39 Fnd.: C 26.78 H 3.55 N 6.16 I 56.27 c) 2,4,6-Triiodo-1,3,5-tris-{ 10-[1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10 tetraazacyclododecanyl]aminoethoxymethyl} benzene 44.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-10-(carboxymethyl) 1,4,7,10-tetrazacyclododecane, 21 ml (164 mmol) of triethylamine, 14.6 g (70.5 mmol) of dicyclohexylcarbodiimide and 8.1 g (70.5 mmol) ofN-hydroxysuccinimide are added to a solution of 15.9 g (23.5 mmol) of 2,4,6-triiodo-1,3,5-tris (aminoethoxymethyl)benzene in 400 ml DMF, and it is stirred for 20 hours at room temperature. Insoluble components are filtered out and evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: 78 dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 29 g (49% of theory) of a colorless solid Elementary analysis: Cld.: C 55.78 H 5.52 N 9.34 115.11 Fnd.: C 55.91 H 5.62 N 9.26 I 14.89 d) 2,4,6-Triiodo-1,3,5-tris-[10-(1,4,7,10-tetraazacyclododecanyl)amino ethoxymethyl]benzene 20 g (7.9 mmol) of 2,4,6-triiodo-1,3,5-tris-{10-[1,4,7-tris-(benzyloxycarbonyl) 1,4,7,10-tetraazacyclododecanyl]aminoethoxymethyl}benzene is carefully mixed at 0 5*C with 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 ml of diethyl ether; the solid that accumulates in this case is suctioned off and rewashed several times with diethyl ether. The residue is dissolved in. 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 10.1 g (97% of theory) of a colorless solid Elementary analysis: Cld.: C 41.20 H 6.45 N 16.01 I 29.02 Fnd.: C 41.09 H 6.42 N 15.98 128.87 79 e) 2,4,6-Triiodo-1,3,5-tris-{ 10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclo dodecanyl]aminoethoxymethyl } benzene 17.7 g (13.5 mmol) of 2,4,6-triiodo-1,3,5-tris-[10-(1,4,7,10-tetraazacyclo dodecanyl)aminoethoxymethyl]benzene is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60'C with 32% NaOH. It is heated for 10 hours to 70'C, whereby the pH of the reaction mixture is continuously readjusted to 9.5. After cooling to room temperature, the pH is set at I with concentrated HCI, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H*-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 14.4 g (58% of theory) of a colorless solid Elementary analysis: Cld.: C 41.25 H 5.60 N 11.45 120.76 Fnd.: C41.20 H5.48 N11.51 120.59 f) 2,4,6-Triiodo-1 ,3,5-tris-{10-[1,4,7-tris-(carboxylatomethyl)-1,4,7,10 tetraazacyclododecanyl, Gd complex]aminoethoxymethyl } benzene 12.7 g (6.9 mmol) of 2,4,6-triiodo-1,3,5-tris-{ 104[1,4,7-tris-(carboxymethyl) 1,4,7,10-tetraazacyclododecanyl]aminoethoxymethyl}benzene is dissolved in 100 ml of 80 water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and-it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 7.4 g (44% of theory) of a colorless solid Water content (Karl-Fischer): 5.9% Elementary analysis (relative to the anhydrous substance): Cld.: C 32.94 H 4.08 N 9.15 116.57 Gd 20.54 Fnd.: C 33.21 H4.12 N 9.17 116.35 Gd 20.31 Example 14 a) 2,4,6-Triiodo-5-[2-(2,2,2-trifluoroacetylamino)-acetylamino]-isophthalic acid dichloride 14.5 ml (200 mmol) of thionyl chloride is added in drops at 0*C within 1 hour to a solution of 34.2 g (200 mmol) of glycine trifluoroacetate in 200 ml of dimethylacetamide. Then, 23.8 g (40 mmol) of 5-amino-2,4,6-triiodoisophthalic acid dichloride (DE 2943777, Schering AG, (priority: 10/26/79)) is added at 0*C and stirred for 4 days at room temperature. The reaction mixture is poured into 5 liters of ice water, and the solid that accumulates is filtered off. For further purification, the filter residue is dissolved in 1000 ml of ethyl acetate, shaken out twice with saturated sodium 81 bicarbonate solution, the organic phase is dried on sodium sulfate, and the solvent is concentrated by evaporation in a vacuum. Yield: 29.3 g (97% of theory) of a colorless solid Elementary analysis: Cld.: C 19.25 H 0.54 N 3.74 Fnd.: C 19.39 H 0.57 N 3.72 b) 5-(2-Aminoacetylamino)-NN-bis-(2-aminoethyl)-2,4,6-triiodoisophthalic acid amide A solution of 10 g (13.3 mmol) of 2,4,6-triiodo-5-[2-(2,2,2-trifluoroacetylamino) acetylamino]-isophthalic acid dichloride in 100 ml of tetrahydrofuran is added in drops to 26.7 ml (399 mmol) of ethylenediamine over 1 hour at room temperature, and it is stirred for 14 more hours. The solid that accumulates is filtered off, rewashed with ethanol, taken up in 100 ml of water, and the pH is set at 8.0 with 1 M lithium hydroxide solution. After concentration by evaporation in a vacuum, it is recrystallized from ethanol. Yield: 6.4 g (68% of theory) of a colorless solid Elementary analysis: Cld.: C 24.02 H 2.74 N 12.01 I 54.38 Fnd.: C 24.276 H 2.79 N 11.98 I 54.25 82 c) 2,4,6-Triiodo-5-(3,6-diaza-1,4,7-trioxo-8-methyloctane-1,8-diyl-{I 10-[1,4,7-tris (carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex] })aminoiso phthalic acid-N, N-bis-(3,6-diaza-4,7-dioxo-8 -methyloctane- 1,8-diyl- { 10-[1,4,7 tris-(carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex] })amide 9.6 g (15.2 mmol)-of the Gd complex of 10-[4-carboxy-2-oxo-3-aza-1 methylbutyl] 1,4,7,1 0-tetraazacyclododecane-1,4,7-triacetic acid (WO 98/24775, Schering AG, (Example 1)) is suspended in 100 ml of DMSO and mixed with 1.96 g (17 mmol) of N-hydroxysuccinimide and 3.3 g (16 mmol) of dicyclohexylcarbodiimide and preactivated for 1 hour. Then, it is mixed with 2.4 g (3.4 mmol) of 5-(2 aminoacetylamino)-N,N-bis-(2-aminoethyl)-2,4,6-triiodoisophthalic acid amide and stirred for 3 days at room temperature under nitrogen. Insoluble components are filtered out, and the solution is poured into 1000 ml of acetone. The solid that accumulates in this case is filtered off and washed in portions with 300 ml of acetone and with 100 ml of diethyl ether. The residue is taken up in 200 ml of water and absorptively precipitated for 2 hours with 30 g of ion exchanger (IRA 67 OH-form) and filtered off. Then, it is absorptively precipitated for 2 hours with 10 g of ion exchanger (IR 267 H-form), filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off, and the solution is concentrated by evaporation to 100 ml. To remove the residual dimethyl sulfoxide, the solution is poured into 1000 ml of acetone, and the precipitate that accumulates is filtered off. The residue is dissolved in 250 ml of water, the conductivity is set at a value of 0.005 mS (pH = 7.0) with a little ion exchanger (H-form and OH-form), it is filtered off and concentrated by evaporation in a vacuum. Yield: 5.7 g (62% of theory) of a colorless solid Water content (Karl-Fischer): 5.7% 83 Elementary analysis (relative to the anhydrous substance): Cld.: C 33.64 H 4.09 N 11.60 115.02 Gd 18.61 Fnd.: C33.77 H4.13 N11.54 115.00 Gdl8.53 Example 15 a) 2,4,6-Triiodo-5-(3,6-diaza-1,4,7-trioxooctane-1,8-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl, Gd complex]})aminoiso phthalic acid-NN-bis-(3,6-diaza-4,7-dioxooctane-1,8-diyl-(10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl, Gd complex]})amide 9.4 g (15.2 mmol) of the Gd complex of 10-[4-carboxy-2-oxo-3-azabutyl] 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (WO 98/24775, Schering AG, (Example 11)) is suspended in 100 ml of DMSO and mixed with 1.96 g (17 mmol) of N hydroxysuccinimide and 3.3 g (16 mmol) of dicyclohexylcarbodiimide and preactivated for 1 hour. Then, it is mixed with 2.4 g (3.4 mmol) of 5-(2-aminoacetylamino)-NN-bis (2-aminoethyl)-2,4,6-triiodoisophthalic acid amide, and it is stirred for 3 days at room temperature under nitrogen. Insoluble components are filtered out, and the solution is poured into 1000 ml of acetone. The solid that accumulates in this case is filtered off and washed in portions with 300 ml of acetone and with 100 ml of diethyl ether. The residue is taken up in 200 ml of water and absorptively precipitated for 2 hours with 30 g of ion exchanger (IRA 67 OH-form) and filtered off. Then, it is absorptively precipitated for 2 hours with 10 g of ion exchanger (IR 267 H-form), filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off, and the solution is concentrated by evaporation to 100 ml. To remove the residual dimethyl sulfoxide, the solution is poured into 1000 ml of acetone, and the precipitate that accumulates is 84 filtered off. The residue is dissolved in 250 ml of water, the conductivity is set at a value of 0.005 mS (pH = 7.0) with a little ion exchanger (H-form and OH-form), it is filtered off and concentrated by evaporation in a vacuum. Yield: 6.1 g (67% of theory) of a colorless solid Water content (Karl-Fischer): 6.4% Elementary analysis (relative to the anhydrous substance): Cld.: C 32.76 H 3.92 N 11.80 115.27 Gd 18.92 Fnd.: C 32.91 H 3.98 N 11.81 1 15.11 Gd 18.67 Example 16 a) 2,4,6-Triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{ 10-[1,4,7-tris (benzyloxycarbonyl)- 1,4,7,1 0-tetraazacyclododecanyl]})aminoisophthalic acid N,N-bis-(3-aza-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris-(benzyloxycarbonyl) 1,4,7,1 0-tetraazacyclododecanyl]})amide 44.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-10-(carboxymethyl) 1,4,7,10-tetrazacyclododecane, 21 ml (164 mmol) of triethylamine, 14.6 g (70.5 mmol) of dicyclohexylcarbodiimide and 8.1 g (70.5 mmol) ofN-hydroxysuccinimide are added to a suspension of 16.5 g (23.5 mmol) of 5-(2-aminoacetylamino)-NN-bis-(2 aminoethyl)-2,4,6-triiodoisophthalic acid amide in 446 ml DMF, and it is stirred for 20 hours at room temperature. Insoluble components are filtered out, and it is evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile 85 solvent: dichloromethane/methanol 20 :1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 30.5 g (51% of theory) of a colorless solid - Elementary analysis: Cld.: C 54.76 H 5.27 N 9.91 114.96 Fnd.: C 54.99 H 5.35 N 9.87 114.65 b) 2,4,6-Triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10-[1,4,7,10-tetraazacyclo dodecanyl]})aminoisophthalic acid-NN-bis-(3-aza-4-oxopentane-1,5-diyl-{10 [1,4,7,10-tetraazacyclododecanyl]})amide 20 g (7.9 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-(10-[1,4,7 tris-(benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid-NN bis-(3-aza-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10-tetraaza cyclododecanyl]})amide is carefully mixed at 0-5*C [with] 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 ml of diethyl ether; the solid that accumulates in this case is suctioned off, and it is rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate, and it is evaporated to the dry state. Yield: 10.1 g (96% of theory) of a colorless solid 86 Elementary analysis: Cld.: C 39.53 H 5.96 N 18.86 I 28.48 Fnd.: C 39.44 H 5.99 N 18.91 128.51 c) 2,4,6-Triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10-[1,4,7-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid-N,N bis-(3 -aza-4-oxopentane-1,5-diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10 tetraazacyclododecanyl] })amide 18.0 g (13.5 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10 [1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid-NN-bis-(3-aza-4-oxopentane 1,5-diyl-{ 10-[1,4,7,10-tetraazacyclododecanyl]})amide is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60*C with 32% NaOH. It is heated for 10 hours to 70'C, whereby the pH of the reaction mixture is readjusted continuously to 9.5. After cooling to room temperature, the pH is set at 1 with concentrated HCl, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H*-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops to 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 15.3 g (61% of theory) of a colorless solid 87 Elementary analysis: Cld.: C 40.05 H 5.26 N 13.56 I 20.65 Fnd.: C 40.22 H 5.29 N 13.49 I 20.56 d) 2,4,6-Triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl, Gd complex] })aminoiso phthalic acid-NN-bis-(3-aza-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10 -tetraazacyclododecanyI, Gd complex] })amide 12.8 g (6.9 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{ 10 [1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid N,N-bis-(3-aza-4-oxopentane-1,5-diyl-{10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraaza cyclododecanyl]} )amide is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 8.3 g (48% of theory) of a colorless solid Water content (Karl-Fischer): 6.9% 88 Elementary analysis (relative to the anhydrous substance): Cld.: C 32.07 H 3.82 N 10.86 116.40 Gd 20.32 Fnd.: C 32.21 H 3.85 N 10.89 116.25 Gd 20.19 Example 17 a) 2,4,6-Triiodo-5-(3-aza-1,4-dioxo-5-methylpentane-1,5-diyl-{10-[1,4,7-tris (benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid N,N-bis-(3-aza-5-methyl-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris (benzyloxycarbonyl)- 1,4,7,1 0-tetraazacyclododecanyl] })amide 45.7 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-10-(1-carboxyethyl) 1,4,7,10-tetrazacyclododecane, 21 ml (164 mmol) of triethylamine, 14.6 g (70.5 mmol) of dicyclohexylcarbodiimide and 8.1 g (70.5 mmol) ofN-hydroxysuccinimide are added to a suspension of 16.5 g (23.5 mmol) of 5-(2-aminoacetylamino)-NN-bis-(2 aminoethyl)-2,4,6-triiodoisophthalic acid amide in 446 ml DMF, and it is stirred for 20 hours at room temperature. Insoluble components are filtered out, and it is evaporated to the. dry state. The residue is taken up in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 28.6 g (47% of theory) of a colorless solid Elementary analysis: Cld.: C 55.27 H 5.42 N 9.75 114.72 Fnd.: C 55.34 H 5.44 N 9.79 114.65 89 b) 2,4,6-Triiodo-5-(3-aza-1,4-dioxo-5-methylpentane-1,5-diyl-{ 10-[1,4,7,10 tetraazacyclododecanyl]})aminoisophthalic acid-NN-bis-(3-aza-5-methyl-4 oxopentane-1,5-diyl-{10-[1,4,7,10-tetraazacyclododecanyl]})amide 20 g (7.7 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxo-5-methylpentane-1,5-diyl (10-[1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid-N,N-bis-(3-aza-5-methyl-4-oxopentane-1,5-diyl-{10-[1,4,7-tris (benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})amide is carefully mixed at 0 5 0 C [with] 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 mlof diethyl ether; -the solid that accumulates in this case is suctioned off and rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 10.2 g (96% of theory) of a colorless solid Elementary analysis:. Cld.: C 40.94 H 6.21 N 18.28 I 27.61 Fnd.: C41.13 H6.17 N 18.32 127.47 90 c) 2,4,6-Triiodo-5-(3-aza- 1,4-dioxo-5-methylpentane- 1,5-diyl-{ 10-[1,4,7-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid-NN bis-(3-aza-5-methyl-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris-(carboxymethyl) 1,4,7,1 0-tetraazacyclododecanyl] })amide 18.6 g (13.5 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxo-5-methylpentane-1,5 diyl-{ 10-[1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid-NN-bis-(3 -aza-5 methyl-4-oxopentane-1,5-diyl-{ 10-[1,4,7,10-tetraazacyclododecanyl]})amide is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and the pH is set at 9.5 at 60'C with 32% NaOH. It is heated for 10 hours to 70'C, whereby the pH of the reaction mixture is readjusted continuously to 9.5. After cooling to room temperature, a pH of 1 is set with concentrated HCl, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, He-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether, and dried in a vacuum. Yield: 14.1 g (55%) of a colorless solid Elementary analysis: Cld.: C 41.06 H 5.46 N 13.26 I 20.02 Fnd.: C 41.34 H 5.52 N 13.31 119.69 91 d) 2,4,6-Triiodo-5-(3-aza-1,4-dioxo-5-methylpentane-1,5-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl, Gd complex] })aminoiso phthalic acid-NN-bis-(3-aza-5-methyl-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)-1,4,7,10-tetraazacyclododecanyl, Gd complex]})amide 13.1 g (6.9 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxo-5-methylpentane-1,5-diyl {10-[1,4,7-tris-(carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})aminoisophthalic acid-NN-bis-(3-aza-5-methyl-4-oxopentane-1,5-diyl-{10-[1,4,7-tris-(carboxymethyl) 1,4,7,10-tetraazacyclododecanyl]})amide is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, a pH of 7.4 is set with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267.H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 7.6 g (44% of theory) of a colorless solid Water content (Karl-Fischer): 5.3% Elementary analysis (relative to the anhydrous substance): Cld.: C33.02.H4.01 N10.66 116.10 Gd19.96 Fnd.: C 33.34 H 4.08 N 10.62 116.01 Gd 19.82 92 Example 18 a) 2,4,6-Triiodo-5-{ methyl [2-(2,2,2-trifluoroacetylamino)-acetyl]amino} isophthalic acid dichloride 14.5 ml (200 mmol) of thionyl chloride is added in drops at 0 0 C within 1 hour to a solution of 34.2 g (200 mmol) of glycine trifluoroacetate in 200 ml of dimethylacetamide. Then, 24.4 g (40 mmol) of 5-amino-2,4,6-triiodoisophthalic acid dichloride (EP 0033426, Sovak, 1/80 US) is added at 0*C, and it is stirred for 4 days at room temperature. The reaction mixture is poured into 5 liters of ice water, and the solid that accumulates is filtered off. For further purification, the filter residue is dissolved in 1000 ml of ethyl acetate, shaken out twice with saturated sodium bicarbonate solution, the organic phase is dried on sodium sulfate, and the solvent is concentrated by evaporation in a vacuum. Yield: 28.7 g (94% of theory) of a colorless solid Elementary analysis: Cld.: C 20.47 H 0.79 N 3.67 Fnd.: C 20.52 H 0.77 N 3.71 b) 5-[(2-Aminoacetyl)-methylamino]-NN-bis-(2-aminoethyl)-2,4,6 triiodoisophthalic acid amide A solution of 10 g (13.1 mmol) of 2,4,6-triiodo-5-{methyl-[2-(2,2,2 trifluoroacetylamino)-acetyl]-amino}-isophthalic acid dichloride in 100 ml of tetrahydrofuran is added in drops to 26.7 ml (399 mmol) of ethylenediamine over 1 hour at room temperature, and it is stirred for 14 more hours. The precipitated solid is filtered off, rewashed with ethanol, taken up in 100 ml of water, and a pH of 8.0 is set 93 with 1 M lithium hydroxide solution. After concentration by evaporation in a vacuum, it is recrystallized from ethanol. Yield: 7.3 g (78% of theory) of a colorless solid Elementary analysis: Cld.: C 25.23 H 2.96 N 11.77 153.31 Fnd.: C 25.44 H 2.98 N 11.81 153.09 c) 2,4,6-Triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10-[1,4,7-tris (benzyloxycarbonyl)- 1,4,7,1 0-tetraazacyclododecanyl]})-methylaminoisophthalic acid-NN-bis-(3-aza-4-oxopentane- 1,5-diyl- {10-[1,4,7-tris-(benzyloxycarbonyl) 1,4,7,10-tetraazacyclododecanyl]})-amide 44.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl) 1 0-(carboxymethyl) 1,4,7,10-tetrazacyclododecane, 21 ml (164 mmol) of triethylamine, 14.6 g (70.5 mmol) of dicyclohexylcarbodiimide and 8.1 g (70.5 mmol) ofN-hydroxysuccinimide are added to a suspension of 16.8 g (23.5 mmol) of 5-[(2-aminoacetyl)-methylamino]-NN-bis-(2 aminoethyl)-2,4,6-triiodoisophthalic acid amide in 446 ml of DMF, and it is stirred for 20 hours at room temperature. Insoluble components are filtered out, and it is evaporated to the dry state. The residue is taken up in 500 ml of ethyl acetate, and it is extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 34.9 g (58% of theory) of a colorless solid 94 Elementary analysis: Cld.: C 54.93, H 5.32 N 9.86 114.88 Fnd.: C 55.12 H 5.39 N 9.81 114.72 d) 2,4,6-Triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10-[1,4,7,10-tetraazacyclo dodecanyl]})-methylaminoisophthalic acid-NN-bis-(3-aza-4-oxopentane-1,5 diyl-{l0-[1,4,7,10-tetraazacyclododecanyl]})-amide 20 g (7.8 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10-[1,4,7 tris-(benzyloxycarbonyl) 1,4,7,1 0-tetraazacyclododecanyl] })methylaminoisophthalic acid-N,N-bis-(3 -aza-4-oxopentane- 1,5-diyl- { 10- [1,4,7-tris-(benzyloxycarbonyl) 1,4,7,10-tetraazacyclododecanyl]})-amide is carefully mixed at 0-5'C [with] 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 ml of diethyl ether; the solid that accumulates in this case is suctioned off and rewashed several times with diethyl ether. The residue is dissolved in 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate, and it is evaporated to the dry state. Yield: 10.0 g (95% of theory) of a colorless solid Elementary analysis: Cld.: C 40.01 H 6.04 N 18.66 I 28.18 Fnd.: C 40.19 H 6.07 N 18.62 I 28.03 95 e) 2,4,6-Triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{ 10-[1,4,7-tris (carboxymethyl)- 1,4,7,1 0-tetraazacyclododecanyl] })-methylaminoisophthalic acid-N, N-bis-(3 -aza-4-oxopentane- 1,5-diyl- { 10-[1,4,7-tris-(carboxymethyl) 1,4,7,1 0-tetraazacyclododecanyl]})-amide 18.2 g (13.5 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10 [1,4,7,1 0-tetraazacyclododecanyl] })-methylaminoisophthalic acid-N, N-bis-(3 -aza-4 oxopentane-1,5-diyl-{ l0-[1,4,7,10-tetraazacyclododecanyl]})-amide is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a. pH of 9.5 is set at 60*C with 32% NaOH. It is heated for 10 hours to 70*C, whereby the pH of the reaction mixture is readjusted continuously to 9.5. After cooling to room temperature, a pH of 1 is set with concentrated HCI, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H-form). Then, it is washed with 2 1 of water, and the acidic eluate is concentrated by evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether and dried in a vacuum. Yield: 15.0 g (59% of theory) of a colorless solid Elementary analysis: Cid.: C 40.39 H 5.33 N 13.46 I 20.32 Fnd.: C 40.53 H 5.37 N 13.41 120.17 96 f) 2,4,6-Triiodo-5-(3-aza- 1,4-dioxopentane- 1,5-diyl- {I 0-[ 1,4,7-tris (carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex]}) methylaminoisophthalic acid-NN-bis-(3-aza-4-oxopentane-1,5-diyl-{10-[1,4,7 tris-(carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex] })-amide 12.9 g (6.9 mmol) of 2,4,6-triiodo-5-(3-aza-1,4-dioxopentane-1,5-diyl-{10 [1,4,7-tris-(carboxymethyl)- 1,4,7,1 0-tetraazacyclododecanyl]})-methylaminoisophthalic acid-N,N-bis-(3 -aza-4-oxopentane- 1,5-diyl- { 10-[1,4,7-tris-(carboxymethyl)- 1,4,7,10 tetraazacyclododecanyl]})-amide is dissolved in 100 ml of water and acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, a pH of 7.4 is set with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1). The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60*C, filtered off and freeze-dried. Yield: 8.7 g (51% of theory) of a colorless solid Water content (Karl-Fischer): 5.8% Elementary analysis (relative to the anhydrous substance): Cld.: C 32.39 H 3.88 N 10.79 116.30 Gd 20.19 Fnd.: C 32.48 H 3.91 N 10.76 116.21 Gd 20.08 97 Example 19 a) 5-[3-(2-Aminoethyl)-ureido]-NN-bis-(2-aminoethyl)-2,4,6-triiodoisophthalic acid amide 100 ml of a 2 M solution of phosgene in toluene is carefully added to a solution of 29.8 g (50 mmol) of 5-amino-2,4,6-triiodoisophthalic acid dichloride (DE 2943777, Schering AG, (priority: 10/26/79)) in 250 ml of dioxane, and it is heated for 24 hours to 60C. Then, the solution is concentrated by evaporation in a vacuum at 80'C, whereby the gases are directed through a 20% aqueous NaOH solution. The residue is dissolved in 200 ml of tetrahydrofuran and added in drops to 66.9 ml (1.0 mol) of ethylenediamine for over 1 hour at room temperature, and it is stirred for 24 more hours. The solid that accumulates is filtered off, rewashed with ethanol, taken up in 200 ml of water, and a pH of 8.0 is set with 1 M lithium hydroxide solution. After concentration by evaporation in a vacuum, it is recrystallized from ethanol. Yield: 19.4 g (53% of theory) of a colorless solid Elementary analysis: Cld.: C 24.71 H 3.04 N 13.45 152.22 Fnd.: C 24.91 H 3.09 N 13.36 151.97 b) 2,4,6-Triiodo-5-(2,5-diaza-1,6-dioxoheptane-1,7-diyl-{ 10-[1,4,7-tris (benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]))-aminoisophthalic acid N,N-bis-(3 -aza-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris-(benzyloxycarbonyl) 1,4,7,10-tetraazacyclododecanyl]})-amide 44.6 g (70.6 mmol) of 1,4,7-tris-(benzyloxycarbonyl)-10-(carboxymethyl) 1,4,7,10-tetrazacyclododecane, 21 ml (164 mmol) of triethylamine, 14.6 g ( 70.5 mmol) 98 of dicyclohexylcarbodiimide and 8.1 g (70.5 mmol) of N-hydroxysuccinimide are added to a suspension of 17.1 g (23.5 mmol) of 5-[3-(2-aminoethyl)-ureido]-NN-bis-(2 aminoethyl)-2,4,6-triiodoisophthalic acid amide in 446 ml DMF, and it is stirred for 20 hours at room temperature. Insoluble components are filtered out, and it is evaporated to the dry state. The residue is taken up. in 500 ml of ethyl acetate and extracted twice with 500 ml each of water. The organic phase is dried on sodium sulfate, the solvent is evaporated to the dry state, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol 20 : 1). The fractions that contain the product are combined and concentrated by evaporation. Yield: 32.7 g (54% of theory) of a colorless solid Elementary analysis: Cld.: C 54.61 H 5.33 N 10.24 114.80 Fnd.: C54.81 H5.35 N10.13 114.72 c) 2,4,6-Triiodo-5-(2,5-diaza-1,6-dioxoheptane-1,7-diyl-{10-[1,4,7,10 tetraazacyclododecanyl]})-aminoisophthalic acid-NN-bis-(3-aza-4-oxopentane 1,5-diyl-{10-[1,4,7,10-tetraazacyclododecanyl]})-amide 25.7 g (10 mmol) of 2,4,6-triiodo-5-(2,5-diaza-1,6-dioxoheptane-1,7-diyl-{10 [1,4,7-tris-(benzyloxycarbonyl)-1,4,7,10-tetraazacyclododecanyl]})-aminoisophthalic acid-N,N-bis-(3-aza-4-oxopentane-1,5-diyl-{10-[1,4,7-tris-(benzyloxycarbonyl) 1,4,7,10-tetraazacyclododecanyl]})-amide is carefully mixed at 0-5 0 C [with] 140 ml of HBr/AcOH (33%) and stirred for 3 hours at room temperature. Then, the reaction mixture is poured into 800 ml of diethyl ether; the solid that accumulates in this case is suctioned off and rewashed several times with diethyl ether. The residue is dissolved in 99 100 ml of water and 100 ml of dichloromethane while being stirred vigorously, and 32% NaOH solution is added until a pH of 10 is reached. The organic phase is separated, the aqueous phase is extracted three times with 50 ml each of dichloromethane, the combined organic phases are dried on magnesium sulfate and evaporated to the dry state. Yield: 12.8 g (94% of theory) of a colorless solid Elementary analysis: Cld.: C 39.57 H 6.05 N 19.48 I 27.87 Fnd.: C 39.71 H 5.99 N 19.56 I 27.61 d) 2,4,6-Triiodo-5-(2,5-diaza-1,6-dioxoheptane-1,7-diyl-{10-[1,4,7-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecanyl]})-aminoisophthalic acid-NN bis-(3-aza-4-oxopentane-1,5-diyl-(10-[1,4,7-tris-(carboxymethyl)-1,4,7,10 tetraazacyclododecanyl]})-amide 18.4 g (13.5 mmol) of 2,4,6-triiodo-5-(2,5-diaza-1,6-dioxoheptane-1,7-diyl-(10 [1,4,7,1 0-tetraazacyclododecanyl] })-aminoisophthalic acid-NN-bis-(3-aza-4 oxopentane-1,5-diyl-{10-[1,4,7,10-tetraazacyclododecanyl]})-amide is dissolved in 75 ml of water, 19.5 g (206.5 mmol) of chloroacetic acid is added, and a pH of 9.5 is set at 60'C with 32% NaOH. It is heated for 10 hours to 70'C, whereby the pH of the reaction mixture is readjusted continuously to 9.5. After cooling to room temperature, a pH of 1 is set with concentrated HC1, and the solution is concentrated by evaporation in a vacuum. The residue is absorptively precipitated with 250 ml of methanol, insoluble. components are filtered out, and the filtrate is concentrated by evaporation. The residue is dissolved in 100 ml of water and added to an ion-exchange column (600 ml, IR 120, H-form). Then, it is washed with 2 1 of water, and the acidic eluate is. concentrated by 100 evaporation. The residue is dissolved in 70 ml of methanol and added in drops in 900 ml of diethyl ether; the solid that accumulates in this case is suctioned off, rewashed several times with diethyl ether, and it is dried in a vacuum. Yield: 14.3 g (56% of theory) of a colorless solid Elementary analysis: Cd.: C 40.07 H 5.34 N 14.09 I 20.16 Fnd.: C 40.24 H 5.31 N 13.99 119.98 e) 2,4,6-Triiodo-5-(2,5-diaza-1,6-dioxoheptane-1,7-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex] })-aminoiso phthalic acid-NN-bis-(3-aza-4-oxopentane-1,5-diyl-{ 10-[1,4,7-tris (carboxylatomethyl)- 1,4,7,1 0-tetraazacyclododecanyl, Gd complex]})-amide 13.0 g (6.9 mmol) of 2,4,6-triiodo-5-(2,5-diaza-1,6-dioxoheptane-1,7-diyl-{ 10 [1,4,7-tris-(carboxymethyl)- 1,4,7,1 0-tetraazacyclododecanyl]})-aminoisophthalic acid N, N-bis-(3 -aza-4-oxopentane- 1,5 -diyl- 10- [1,4,7-tris-(carboxymethyl)- 1,4,7,1 0-tetraaza cyclododecanyl]})-amide is dissolved in 100 ml of water and.acidified by adding 3 ml of acetic acid. 3.7 g (10.4 mmol) of gadolinium oxide is added, and it is refluxed for 6 hours. After complexing is completed, the pH is set at 7.4 with ammonia, and it is chromatographed on silica gel (mobile solvent: dichloromethane/methanol/ammonia: 10/10/1): The fractions that contain the product are combined and absorptively precipitated with 10 g of ion exchanger (IR 267 H-form) for 2 hours and filtered off, then, it is absorptively precipitated with 10 g of ion exchanger (IRA 67 OH-form) for 2 hours, filtered off, mixed with 2 g of activated carbon, heated for 2 hours to 60'C, filtered off and freeze-dried.
101 Yield: 7.1 g (41% of theory) of a colorless solid Water content (Karl-Fischer): 6.3% Elementary analysis (relative to the anhydrous substance): Cid.: C 32.19 H 3.90 N 11.32 116.19 Gd.20.07 Fnd.: C 32.34 H 3.91 N 11.28 116.07 Gd 19.96 Pharmacological Examples CT Studies with Example 1B By way of example, the suitability of the described compound class was examined in Example lB with the aid of computer tomography (CT) of rats. For the CT studies, a Siemens Somatom CR was available. The 5-second image was prepared with a layer -thickness of 2 mm and a tube voltage of 125 kV. Substance lB was formulated as an aqueous solution at a concentration of 0.17 mol/1 (corresponds to 145 mg (1 +Gd)/mI. Male Wistar rats (400 g of body weight) were scanned before (Fig. 1 a) and after intravenous injection (Fig. 1) of lB in a dose of 0.15 mmol/kg (corresponds to 127 mg of (I+Gd)/kg).
P \WPDOCS\Hjw\Spe 2\1256%71 doc.7/01/2008 - 102 Despite the small size of the animal being examined, a very clear contrasting of the blood-conveying vessels (A) and the renal cortex (N) could itself be observed with the low dose of 127 mg of (I+Gd). This early phase reflects the blood perfusion of the renal cortex. As early as 15 minutes~later in the parenchyma phase, the renal pelvis was 5 contrasted, which can be attributed to a quick renal excretion of the substance (FIG. 2). MRT Studies with Example 1B The same substance (IB) was examined with the aid of magnetic resonance tomography (MRT) as a contrast medium. 10 The MRT studies were performed on a 1.5 T device (Siemens Symphonie with 40 mT/m gradients). 400 g Wistar rats were examined with TI-weighted image sequences (angiography TR 2.54 ms, TE 1.12 ms und a= 400 or organ visualization TR 54 ms, TE 4.8 ms and a= 40*). The angiography (MRA, FIG. 3) was from 0-60 seconds p.i., and the organ visualization (FIGS. 4a and b) was prepared 15 minutes after the 15 injection. Substance lB was formulated as an aqueous solution at a concentration of 0.17 mol/l (corresponds to 0.5 mol ofGd/l) and was intravenously injected in a dose of 0.03 mmol of substance or 0.1 mmol of Gd/kg. The MRA has an excellent ability to visualize the large arteries (aorta, femoral artery) as well as the heart. 20 In the whole-body image (FIG. 4b), a clear contrasting of liver (L) as well as kidneys (renal pelvis=N) can be detected. The ureter (U) could also be visualized, which also emphasized the quick renal elimination of the substance. This combined CT and MR study demonstrates the dual uses of this new compound class. Excellent contrast enhancement was demonstrated in CT and in MR. 25 The clinical use of these compounds is conceivable, for example, in a high-resolution MultiSlice CT (visualization of the coronary vessels). After that, a delayed MRT is performed to evaluate the vitality of the myocardium. To this end, a second injection of a contrast medium is not necessary. 30 Phantom Studies with Example 3F in Comparison to Gadovist and lopromilde The relative X-ray attenuation of Example 3F was determined at concentrations P.\WPDOCS\1jw\Spcs 2\12569671doc.17/01/2008 - 103 of 0.05, 0.1 and 0.2 mol/l of substance, equivalent to 0.3, 0.6 and 1.2 mol/ of opacifying elements (Gd+iodine), compared to equimolar concentrations of iopromide and gadobutrol. To this end, a phantom was used, in which dilutions of the starting formulations (Example 3F-0.27M, Ultravist* 300 mg of I/ml equivalent to 0.788 mol/l of 5 iopromide and gadobutrol 1 mol/l) in distilled water was pipetted into well-plates (Oster 3524). A milliliter of each dilution was pipetted in each case into a well-plate, which corresponded to a height of 0.5 cm. The finish-pipetted well-plate was positioned on the horizontal patient table of the C-arm x-ray device (stenoscope D6, General Electric) in the beam path, and above it, a plastic container with a 17-cm water column was set on 10 the well-plate to simulate soft-tissue. absorption and radiation-hardening of the x-ray radiation as under in-vivo conditions. The x-ray images were recorded in the "high pulse" modality with the DSM x ray device stenoscope D6 (General Electric) with a cesium filter/iodine intensifier of 16 cm and a 2 mm aluminum filter with various voltages of the x-ray anode. 15 All images were recorded after manual selection of the anode voltage of x-ray tubes and variation of mA to optimize the image contrast in the respective anode voltage. The images of stenoscope D6 were then transferred into an image-analyzing device (Quantimet 500+, Leica) and visualized on a scale of 256 gray-scale values. For quantitative gray-scale determination, a circular ROI~(region of interest) for each well 20 was analyzed, and the background was subtracted in the respective anode voltage. The measured gray values of Example 3F, iopromide and gadobutrol, were applied against the respective concentration and a linear regional analysis was performed. The increase in compensating lines was calculated in this case, and the ratio of straight lines between the various contrast media was determined. 25 Representative x-ray images of the above-described phantom are visualized in FIG. 5. The ratio between the concentrations of Example 3F, iopromide and gadobutrol was linear in all cases. The evaluation showed a significantly higher x-ray absorption of Example 3F than iopromide and gadobutrol at equimolar concentrations (FIG. 5). 30 In the evaluation of x-ray images, Example 3F showed a 3.08 x-higher x-ray absorption than iopromide and a 3.77 x-higher x-ray absorption than gadobutrol with P:\WPDOCS\Hj\Spec 2\1256%71 do.17/01/2008 -104 110 kV and equimolar concentrations. Still higher differences in the x-ray absorption of Example 3F can be expected for higher anode voltages, as they are used in modem x-ray CT-processes (helicoidal and mull-line CT). Radiation hardening that occurs in addition under in-vivo conditions promotes additional elements, such as, e.g., Gd, Dy, Yb or Bi. 5 The phantom studies confirm that Example 3F has an excellent x-ray absorption and is suitable for use in modem I)SA and CT, especially multi-line CT. Distribution Coefficient The distribution coefficient of Example 3F was determined in comparison to 10 Gadovist, iopromide and iotrolan in 1-butanol and tris-HCI buffer at pH 7.6. The contrast media were dissolved in the buffer at a final concentration of 0.1 mmol of Gd/l, and the iodine-containing contrast media were used with a starting concentration of 1 mg of I/mi. Table 1: Distribution Coefficient of Example 3F in Comparison to Commercially Available MR- and X-ray Contrast Media Distribution Coefficient of 20 Substance Butanol/Water Example 3F 0.0002 ± 0.0001 Gadobutrol 0.006 ± 0.0007 30 lopromide 0.051 0.003 lotrolan 0.0065 0.002 The data in Table I confirm that Example 3F is a very hydrophilic substance with a low distribution coefficient of butanol/water and has even better values than the very well-tolerated MR-contrast medium Gadovist. In comparison to this, the commercially 40 available iodine-containing compound lopromide has a much lower hydrophilia with up to a 255x-higher distribution coefficient of butanol/water (0.051 vs. 0.0002).
P.\WPDOCS\ijw\Specs 2U256%71.doc-17/01/2008 -105 IC-50/LD-50 Correlation To determine the IC-50, the neutral red test was used in epithelial cells of the distal renal tubule. In addition, this test is very helpful for predicting with high accuracy the LD-50 values of newly synthesized compounds. 5 Epithelial cell line MDCK of the renal distal renal tubule of a canine kidney (ECACC No. 85011435) was incubated from 10,000 cells/well in Alpha MEM Eagle (10% fetal bovine serum) at 37 0 C. and 5% C0 2 , 95% atmospheric humidity for 20 hours with various Examples 1B, 3F and 5F. Neutral red was used as an indicator for cell viability and for measuring lyosornal integrity and employed to determine those contrast 10 medium concentrations in which a 50% reduction of cell viability (IC-50) occurred after 24 hours. Four independent replicates were tested for each concentration of contrast medium. The results are summarized in Table 2. Compared to the reference compound for MR contrast media, Gadovist showed a strong increase in compatibility. The latter is 15 a reference compound in clinical practice and a contrast medium with proven excellent compatibility. The highest compatibility was found for Example 3F with 1170 pmol of I eq/ml. Table 2: Comparison of IC 50 Values of Different Examples According to the Invention with Gadobutrol as well as the LD 50 Value to be Expected in Mice. "Expected" LD 5 o of 25
IC
5 0 Substance Mice (r 2 : 0.93) pmol of I eq/ml mmol of I eq/kg Gadovist 153 32 35 Example 1B 930 165 Example 3F 1170 195 Example 5G 788 143 P.\WPDOCS\1Ijw\Specs 2\2569671 doc.171011200S -106 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. 5 In the foregoing and in the examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated. The entire disclosure of all applications, patents and publications, cited herein and of corresponding German application No. 10307759.6, filed Feb. 19, 2004, and U.S. Provisional Application Ser. No. 60/452,053, filed Mar. 6, 2003 are incorporated by 10 reference herein. The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples. From the foregoing description, one skilled in the art can easily ascertain the 15 essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. BRIEF DESCRIPTION OF DRAWINGS 20 FIG. I Illustrates Male Wistar rats which were scanned before (FIG. I a) and after intravenous injection (FIG. Ib) of lB in a dose of 0.15 mmol/kg (corresponds to 127 mg of (I=Gd)/kg). FIG. 2 Illustrates CT Image of a Rat 15 Minutes after I.V. Injection of IB. FIG. 3 Illustrates IVIRA 7.5 Seconds After I.V. Injection of IB in Rats. 25 FIG. 4 Illustrates baseline organ visualization (FIG. 4a) and organ visualization that was prepared 15 minutes after the injection (FIG. 4b). FIG. 5 Illustrates comparison of X-ray Absorption of Example 3F, Gadobutrol and lopromide X-ray images of the phantom at 60 and 110 kV anode voltage are recorded with the C-arm device stenoscope D6. 30 FIG. 6 Illustrates relative X-ray Absorption of Example 3F in Comparison with Gadobutrol and Iopromide at Various Anode Voltages of X-ray Tubes.

Claims (19)

1. A metal complex of formula I KA' A'K Hal HI A'K A 2 K in which Hal stands for bromine or iodine, A' stands for -CONR'-(CH 2 )n-NR 2 -(CO-CHZ-NH)m-CO-CHZ 2 *, -CONR'-(CH 2 )p-(CONR 2 Cf 2 )m-CHOH-CHr-*, -CH 2 0-(CH 2 )p-CHOH-CH 2 -*, -CH 2 -0(CH 2 )n-NRI-(CO-CHZI-NH)m-CO-CHZ 2 -*, or -CH 2 -NR'-CO-(CHZ'-NH-CO)m-CHZ 2 _*, A2 independently has the same meaning as A' or in the case that A' has the meaning first mentioned above can also stand for the radical-NR' CO-(NR')m-(CH 2 )p-NR 2 -(CO-CHZ' -NH)m-CO-CHZ 2 *, * designates the binding site to K, R1 and R2 mean, independently of one another, a hydrogen atom, CI C 2 -alkyl group or a monohydroxy-Ci C 2 -alkyl group, Z' and Z2 mean, independently of one another, a hydrogen atom or a methyl group, n means the number 2-4, m means the number 0 or 1 and p means the number 1-4, K stands for a macrocyclic compound of formula ]a P.\WPDOCS\Hjw\Specs 2\12569671 doc-17/01/2008 - 108 (IA) coox KN'coox COOX with X meaning a hydrogen atom or-a metal ion equivalent of atomic numbers 20-29, 39, 42, 44 or 57-83, provided that at least two X stand for metal ion equivalents, and optionally present free carboxy groups optionally are present as salts of organic and/or inorganic bases or amino acids or amino acid amides.
2. A metal complex according to claim 1, wherein A' stands for -CONIH(CH 2 ) 2 ; 3 NHCOCH 2 NHCOCH(CH 3 )-, -CONH(CH 2 ) 2 3 NHCOCH 2 NHCOCH 2 -, -CONH(CH 2 ) 2 ; 3 NHCOCfH2-, -CONH(CH 2 ) 2 ; 3 NHCOCH(CH 3 )-, -CONHCH 2 CH(OH)CH 2 -, -CON(CH 3 )CH 2 CH(OH)CH 2 -, -CH 2 0CH 2 CH(OH)CH 2 -. -CONHCH 2 CONHCH 2 CH(OH)CH 2 -, -CH 2 NHCOCH 2 -, -CH 2 NHCOCH(CH 3 )-, -CH 2 NHCOCH 2 NHCOCH 2 -, -CH 2 NHCOCH 2 NHCOCH(CH 3 )-, -CH 2 0(CH 2 ) 2 NHCOCH 2 -, -CON(CH 2 CH 2 OH)CH 2 CH 2 NHCOCH 2 -, or -CH 2 O(CH 2 ) 2 N(CH 2 CH 2 OH)COCH 2 -.
3. A metal complex according to claim 1, wherein A 2 stands for -NHCOCH 2 NHCOCH 2 NHCOCH(CH 3 )-, -NHCOCH 2 NHCOCH 2 NHCOCH 2 -, PAWPDoCSInjwiSpecs 2\2s69671doc.-17o/2OOS - 109 -NHCOCH 2 NHCOCH 2 -, -NHCOCH 2 NHCOCH(CH3)-, -N(CH 3 )COCH 2 NHiCOCH2-, -NH CONH(CH 2 ) 2 NHCOCH 2 -, -NHCOCH 2 N(CH 2 CH 2 OH)COCH 2 -, or -N(CH 3 )COCH 2 N(CH 2 CH 2 OH)COCH 2 -.
4. A metal complex according to claim 1, wherein at least one X stands for a metal ion equivalent of atomic numbers 21-29, 42, 44, or 58-70.
5. A metal complex according to claim 4, wherein at least one X stands for a metal ion equivalent of gadolinium(III), dysprosium(III), europium(III), iron(IlI) or manganese(II).
6. A pharmaceutical composition that contains at least one metal complex according to claim 1 and one or more additives suitable for use in a galenical formulation.
7. A method of x-ray diagnosis comprising administering to a patient at least one metal complex according to claim I and performing x-ray diagnosis.
8. A method of MRT diagnosis comprising administering to a patient at least one metal complex according to claim 4 for and performing MRT diagnosis.
9. A pharmaceutical composition that contains a metal complex according to claim 1 in a molar ratio of 2000:1 to 1:1.
10. A pharmaceutical composition according to claim 6, wherein said at least one metal complex is dissolved or suspended in water or in a physiologically acceptable salt solution at a concentration of 0.001 to 1 mol/l. P.\WPDOCS\Hjw\Specs 2\1256%71 doc.17/01/2008 -110
11. A method for x-ray diagnosis or MR diagnosis of a cerebral infarction, a tumor of the liver, a space-occupying process in the liver, a tumor of the abdomen, a kidney, a muscle-skeleton system, or a blood vessel, comprising administering to a patient at least one metal complex according to claim 1, and performing x-ray diagnosis or MR diagnosis.
12. A process for preparing a metal complex according to claim 1, comprising a) reacting a triiodo- or tribromoaromatic compound of formula II Y 1 -NHR' Hal Hal (II) R'NH-Y Y 2 -NHR' .Hal with a macrocyclic compound of formula III W IIl N O"C-B'-N N-W N W in which C'O stands for a -COOH-- or activated carboxyl group, W stands for a protective group or a -CH 2 COOX' group with X' in the meaning of X as defined in claim 1 or a protective group and -Y-NR'-CO-B'-, which forms upon reaction of a Y'NHRI group of a compound of formula II with the OxCB group of a compound of formula III, stands for the radical A' in the meaning of -CO NR- (CH 2 )n-NR2-(CO-CHZ -NH)m-CO-CHZ 2 or -CH 2 -0- (CH 2 )n NR'-(CO-CHZ-NH)m-CO-CHZ 2 - and -Y 2 -NR'-CO-B'-, which forms upon reaction of the Y2 NHR group of a compound of formula II with the O'CBl- P:\WPDOCS\Kjw\Specs 2\1256%71 doc.17/01/2008 group of a compound of formula 1I1, stands for -Y1-NR'-CO-B'- or for the case that -Y'-NR'-CO-B- has the meaning first mentioned above, the latter also stands for -NR -CO- (NR' )m(CH 2 )p-NR 2 -(CO-CHZ-NH)m-CO-CHZ 2 -, and then optionally removing protective group W and introducing the radical CH 2 COOX, or optionally removing the protective group that stands for X' and then reacting with a metal oxide or metal salt of an element of atomic numbers 20-29, 39, 42, 44 or 57-83, or b) reacting a triiodo- or tribromoaromatic compound of formula IV (IV) CIO Hal, Hal eno c-O Hal with a macrocyclic compound of formula V COOrI N*' COOX' R'NH-Y3- N N N,, QCOOX' in which -CxO and X' have the above-mentioned meaning and -CO-NR'-Y 3 -, which forms upon reaction of the Y 3 NHR' group of a compound of formula V with the O'C-- group of a compound of formula IV, stands for radical A' in the meaning of CONR'-(CH 2 )p-(CONR2CH 2 ),-CH(OH)CH 2 -, and then optionally removing the protective group that stands for X' and then reacting with a metal oxide or metal salt of an element of atomic numbers 20-29, 39, 42, 44 or 57-83, or c) reacting a triiodo- or tribromoaromatic compound of formula VI (VI) A' Hal Hal A1 A' Hal P:\WPDOCS\HjwSpecs 2\N2569671 doc.17/0112008 - 112 in which A' stands for a radical 0 -CH2-0--(CH2)p-CH-CH2- with a cyclene of formula VII (VII) W' H-N N-W' W' in which W' stands for a hydrogen atom or a protective group, removing the optionally present protective groups and then introducing radical CH 2 COOX to form a metal complex of formula I with A in the meaning of radical CH 2 -0-(CH 2 )p-CHOH-CH 2 -, or d) reacting a triiodo- or tribromoaromatic compound of formula VIII (Vill) CH 2 -Nucleofug HAI Hal Nucleofug-CH 2 CH 2 -Nucleofug Hal [Nucleofug - nucleofuge] in which Nucleofuge stands for a nucleofuge group, with a macrocyclic compound of formula IX (IX) W N RIHN-CO-B 2 -N N-W N W in which Rl and W have the above-rentioned meanings, and B 2 stands for the radical (CHZ-NHCO)m-CHZ 2 , and then further processing as indicated under a), such that metal complexes of formula I are obtained with A' in the meaning of radical -CH 2 - P \WPDOCS\Hjw\Spccs 2\1256%71 do.-7/01/2008 -113 NR'-CO-(CHZ-NHCO)m-CHZ2, then in the metal complexes, obtained according to a)-d), of formula I, still present acid hydrogen atoms are optionally substituted by cations of inorganic or organic bases, amino acids or amino acid amides.
13. A process for preparing a pharmaceutical composition according to claim 6, comprising bringing into a composition said at least one metal complex and the one or more additives suitable for use in a galenical formulation.
14. A pharmaceutical composition according to claim 6, which is in a suitable form for enteral or parenteral administration.
15. A metal complex according to claim 1, wherein A] stands for -CONH(CH 2 ) 2 ; 3 NHCOCHI 2 NHCOCH(CH 3 )-, -CONI(CH 2 ) 2 ; 3 NHCOCH 2 NHCOCH 2 )-, -CONH(CH 2 ) 2 ; 3 NHCOCH 2 )-, -CONH(CH 2 ) 2 ; 3 NHCOCH(C 3 )-, -CONHCH 2 CH(OH)CH 2 -- , -CON(CH 3 )CH 2 CH(OH)CH 2 -, -CH 2 0CH 2 CH(OH)CH 2 -CONHCH 2 CONHCH 2 C.H(OH)CH 2 -, -CH 2 NHCOCH 2 -, -CH 2 NHCOCH(CH 3 )-, -CH 2 NHCOCH 2 NHCOCH 2 -, -CH 2 NHCOCH 2 NHCOCH(CH 3 )-, -CH 2 O(CH 2 ) 2 NHCOCH 2 -, or -CH 2 O(CH 2 ) 2 N(CH 2 CH 2 OH)COCH 2 -.
16. A metal complex according to claim 1, wherein A2 stands for -NHCOCH 2 NHCOCH 2 NHCOCH(CH 3 )-, -NHCOCH 2 NHCOCH 2 NHCOCH 2 -, -NHCOCH 2 NHCOCH 2 -, P:\WPDOCS\Hjw\Spec 2\N 2569671 doc.- 01/2008 -114 -NHCOCH 2 NHCOCH(CH 3 )-, -N(CH 3 )COCH 2 NHCOCH2-, -NHCOCH 2 N(CH 2 CH 2 OH)COCH 2 -, or -N(CH 3 )COCH 2 N(CH 2 CH 2 OH)COCH 2 -.
17. A process according to claim 12, wherein the nucleofuge group is F, CI, Br, I, -OTs, -OMs, OH, -O F. -O - O2 NNO2 N02 F F 0 -O-N
18. A pharmaceutical composition that contains a metal complex according to claim 1 in a molar ratio of 49:1 to 4:1.
19. A process according to claim 12, wherein the nucleofuge group is F, CI, Br, I, OH, - N' -O F. -O N2, - -- O NO F F INO 0 -0 0
AU2003290032A 2003-02-19 2003-12-12 Trimeric macrocyclically substituted benzene derivatives Expired - Fee Related AU2003290032B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10307759A DE10307759B3 (en) 2003-02-19 2003-02-19 Trimers of macrocyclically substituted benzene derivatives, their production and use as contrast media and pharmaceutical compositions containing them
DE10307759.6 2003-02-19
PCT/EP2003/014149 WO2004074267A1 (en) 2003-02-19 2003-12-12 Trimeric macrocyclically substituted benzene derivatives

Publications (2)

Publication Number Publication Date
AU2003290032A1 AU2003290032A1 (en) 2004-09-09
AU2003290032B2 true AU2003290032B2 (en) 2009-04-23

Family

ID=32891780

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003290032A Expired - Fee Related AU2003290032B2 (en) 2003-02-19 2003-12-12 Trimeric macrocyclically substituted benzene derivatives

Country Status (16)

Country Link
EP (1) EP1594851A1 (en)
JP (1) JP2006514664A (en)
KR (1) KR20050105474A (en)
CN (1) CN1753878A (en)
AR (1) AR043205A1 (en)
AU (1) AU2003290032B2 (en)
BR (1) BR0318125A (en)
CA (1) CA2516467A1 (en)
CR (1) CR7937A (en)
DE (1) DE10307759B3 (en)
EC (1) ECSP056026A (en)
MX (1) MXPA05008781A (en)
NO (1) NO20054291L (en)
RU (1) RU2005128834A (en)
WO (1) WO2004074267A1 (en)
ZA (1) ZA200507437B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DE102004023093B3 (en) 2004-05-05 2006-03-02 Schering Ag Trimere macrocyclic substituted halogen-benzene derivatives
DE102004026103A1 (en) * 2004-05-25 2005-12-22 Schering Ag Trimere macrocyclic substituted aminoisophthalic acid-halogenated benzene derivatives
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
DE102007058220A1 (en) 2007-12-03 2009-06-04 Bayer Schering Pharma Aktiengesellschaft New metal complexes useful e.g. for manufacturing agent for X-ray diagnostics and magnetic resonance tomography-diagnostics of brain infarcts and liver tumor, and/or space-process in liver and abdomen tumors and musculoskeletal tumors
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2012027727A2 (en) * 2010-08-26 2012-03-01 Kunyuan Cui Lipomacrocycles and uses thereof
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN104721844B (en) * 2015-02-02 2017-11-03 湖北大学 A kind of new CT, MRI, the functional microsphere of rare-earth fluorescent three and its preparation method and application
CN104672259B (en) * 2015-02-02 2017-04-05 湖北大学 A kind of rare-earth europium containing iodine (III) complex and its preparation method and application
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CN105254529B (en) * 2015-09-21 2017-05-31 西南石油大学 A kind of preparation method of tree-like schiff bases corrosion inhibiter
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CN107445911B (en) * 2017-06-19 2019-07-05 南京科技职业学院 Two core mr contrast agents containing gadolinium of one kind and its preparation and application
JOP20210114A1 (en) 2018-11-23 2023-01-30 Bayer Ag Formulation of contrast media and process of preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324503A (en) * 1992-02-06 1994-06-28 Mallinckrodt Medical, Inc. Iodo-phenylated chelates for x-ray contrast
ATE195432T1 (en) * 1993-06-02 2000-09-15 Bracco Spa IODINATED PARAMAGNETIC CHELATES AND THEIR USE AS CONTRAST AGENTS
FR2736051B3 (en) * 1995-06-29 1997-09-26 Guerbet Sa METAL COMPLEXES OF POLYAMINOACIDS, THEIR PREPARATION PROCESS AND THEIR USE IN DIAGNOSTIC IMAGING
FR2793795B1 (en) * 1999-05-21 2001-08-03 Guerbet Sa ISOMERS OF TETRAMIDS OF THE ACID GADOLINIUM COMPLEX (1,4,7,10-TETRAZACYCLODODECANE) 1,4,7,10-TETRA (2-GLUTARIC) THEIR PREPARATION PROCESS AND THEIR APPLICATION IN MEDICAL IMAGING
FR2794744B1 (en) * 1999-06-09 2001-09-21 Guerbet Sa METAL COMPLEXES OF BICYCLIC POLYAMINOACIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN MEDICAL IMAGING

Also Published As

Publication number Publication date
DE10307759B3 (en) 2004-11-18
ZA200507437B (en) 2007-02-28
CN1753878A (en) 2006-03-29
AU2003290032A1 (en) 2004-09-09
NO20054291D0 (en) 2005-09-16
WO2004074267A1 (en) 2004-09-02
KR20050105474A (en) 2005-11-04
RU2005128834A (en) 2006-03-20
BR0318125A (en) 2006-02-07
CR7937A (en) 2006-02-07
JP2006514664A (en) 2006-05-11
MXPA05008781A (en) 2006-03-10
AR043205A1 (en) 2005-07-20
NO20054291L (en) 2005-11-17
EP1594851A1 (en) 2005-11-16
CA2516467A1 (en) 2004-09-02
ECSP056026A (en) 2006-01-27

Similar Documents

Publication Publication Date Title
AU2003290032B2 (en) Trimeric macrocyclically substituted benzene derivatives
JPH11510834A (en) Cascade polymer complex, method for producing the same, and medicament containing them
US20030206865A1 (en) Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy
JPH08510458A (en) Iodinated paramagnetic chelates and their use as contrast agents
JPH09502198A (en) Chelating agent as contrast enhancer
US7385054B2 (en) Trimeric, macrocyclically substituted halo-benzene derivatives
US7208140B2 (en) Trimeric macrocyclic substituted benzene derivatives
JP2004506631A (en) Perfluoroalkyl-containing complex having sugar residue, method for producing the same and use thereof
US20080213187A1 (en) Novel cascade polymer complexes, processes for their preparation and pharmaceutical compositions comprising them
CA2362703A1 (en) Perfluoroalkylamide, the production thereof and the use thereof in diagnostics
RU2289579C2 (en) Perfluoroalkyl-containing complexes with polar residues, method for their preparing, pharmaceutical agent
US20060120965A1 (en) Trimeric, macrocyclically substituted aminoisophthalic acid-halo-benzene derivatives
KR19990076638A (en) Cascade polymer complexes, process for their preparation and pharmaceuticals containing them
DE102007058220A1 (en) New metal complexes useful e.g. for manufacturing agent for X-ray diagnostics and magnetic resonance tomography-diagnostics of brain infarcts and liver tumor, and/or space-process in liver and abdomen tumors and musculoskeletal tumors
JP2000514850A (en) Pseudopolyrotaxane
AU734983B2 (en) Macrocyclic metal complex carboxylic acids, Their use as well as process for their production
US6461587B1 (en) Perfluoroalkylamides, their production and their use in diagnosis
JP2010506862A (en) Metal chelates with perfluorinated PEG groups, methods for their formulation and use thereof
US5919433A (en) Macrocyclic metal complex carboxylic acids, their use as well as process for their production

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee